1. Field of the Invention
This invention is directed to novel phosphonate derivatives of glycopeptide antibiotics and related compounds. This invention is also directed to pharmaceutical compositions containing such glycopeptide phosphonate derivatives, methods of using such glycopeptide phosphonate derivatives as antibacterial agents, and processes and intermediates useful for preparing such glycopeptide phosphonate derivatives.
2. Background
Glycopeptides (e.g. dalbaheptides) are a well-known class of antibiotics produced by various microorganisms (see Glycopeptide Antibiotics, edited by R. Nagarajan, Marcel Dekker, Inc. New York (1994)). These complex multi-ring peptide compounds are very effective antibacterial agents against a majority of Gram-positive bacteria. Although potent antibacterial agents, the glycopeptides antibiotics are not used in the treatment of bacterial diseases as often as other classes of antibiotics, such as the semi-synthetic penicillins, cephalosporins and lincomycins, due to concerns regarding toxicity.
In recent years, however, bacterial resistance to many of the commonly-used antibiotics has developed (see J. E. Geraci et al., Mayo Clin. Proc. 1983, 58, 88-91; and M. Foldes, J. Antimicrob. Chemother. 1983, 11, 21-26). Since glycopeptide antibiotics are often effective against these resistant strains of bacteria, glycopeptides such as vancomycin have become the drugs of last resort for treating infections caused by these organisms. Recently, however, resistance to vancomycin has appeared in various microorganisms, such as vancomycin-resistant enterococci (VRE), leading to increasing concerns about the ability to effectively treat bacterial infections in the future (see Hospital Infection Control Practices Advisory Committee, Infection Control Hospital Epidemiology, 1995, 17, 364-369; A. P. Johnson et al., Clinical Microbiology Rev., 1990, 3, 280-291; G. M. Eliopoulos, European J. Clinical Microbiol., Infection Disease, 1993, 12, 409-412; and P. Courvalin, Antimicrob. Agents Chemother, 1990, 34, 2291-2296).
A number of derivatives of vancomycin and other glycopeptides are known in the art. For example, see U.S. Pat. Nos. 4,639,433; 4,643,987; 4,497,802; 4,698,327; 5,591,714; 5,840,684; and 5,843,889. Other derivatives are disclosed in EP 0 802 199; EP 0 801 075; EP 0 667 353; WO 97/28812; WO 97/38702; WO 98/52589; WO 98/52592; and in J. Amer. Chem. Soc., 1996, 118, 13107-13108; J. Amer. Chem. Soc., 1997, 119, 12041-12047; and J. Amer. Chem. Soc., 1994, 116, 4573-4590.
Despite the above referenced disclosures, a need currently exists for novel glycopeptide derivatives having effective antibacterial activity and an improved mammalian safety profile. In particular, a need exists for glycopeptide derivatives which are effective against a wide spectrum of pathogenic microorganism, including vancomycin-resistant microorganisms, and which have reduced tissue accumulation and/or nephrotoxicity.
The present invention provides novel glycopeptide phosphonate derivatives having highly effective antibacterial activity and an improved mammalian safety profile. More specifically, the glycopeptide phosphonate derivatives of the invention unexpectedly exhibit reduced tissue accumulation and/or nephrotoxicity when administered to a mammal.
Accordingly, this invention provides glycopeptide compounds substituted with one or more (e.g., 1, 2 or 3) substituents comprising one or more (e.g., 1, 2 or 3) phosphono (xe2x80x94PO3H2) groups; or a pharmaceutically acceptable salt, stereoisomer, or prodrug thereof. Preferably, the glycopeptide compound is substituted with one or two substituents comprising one or two phosphono groups. More preferably, the glycopeptide compound is substituted with one substituent comprising one or two phosphono groups, preferably one phosphono group. Optionally, the glycopeptide compounds of this invention may also be substituted with other substituents not comprising a phosphono group, provided that at least one substituent comprises one or more phosphono groups.
Accordingly, in one preferred embodiment, this invention provides a glycopeptide compound substituted at the C-terminus with a substituent comprising one or two phosphono (xe2x80x94PO3H2) groups; or a pharmaceutically acceptable salt, stereoisomer, or prodrug thereof. Preferably, the phosphono-containing substituent is attached to the carbonyl group at the C-terminus through an amide bond, an ester bond, or a thioester bond; more preferably, through an amide bond. Preferably, the phosphono-containing substituent comprises one phosphono group. Particularly preferred phosphono-containing substituents at the C-terminus include phosphonomethylamino, 3-phosphonopropylamino and 2-hydroxy-2-phosphonoethylamino.
In another preferred embodiment, this invention provides a glycopeptide compound substituted at the R-terminus (on the resorcinol ring) with a substituent comprising one or two phosphono (xe2x80x94PO3H2) groups; or a pharmaceutically acceptable salt, stereoisomer, or prodrug thereof. Preferably, the phosphono-containing substituent is attached to the R-terminus (i.e., the resorcinol ring) through the nitrogen atom of an aminomethyl group attached to the R-terminus. Preferably, the phosphono-containing substituent comprises one phosphono group. Particularly preferred phosphono-containing substituents at the R-terminus include N-(phosphonomethyl)aminomethyl; -(2-hydroxy-2-phosphonoethyl)aminomethyl; N-carboxymethyl-N-(phosphonomethyl)aminomethyl; N,N-bis(phosphonomethyl)aminomethyl; and N-(3-phosphonopropyl)aminomethyl.
In still another preferred embodiment, this invention provides a glycopeptide compound substituted at the C-terminus and at the R-terminus with a substituent comprising one or two phosphono (xe2x80x94PO3H2) groups; or a pharmaceutically acceptable salt, stereoisomer, or prodrug thereof. Preferably, the phosphono-containing substituents each comprises one phosphono group.
A preferred compound of the invention is a glycopeptide of formula I: 
wherein:
R1 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic and xe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x; or R1 is a saccharide group optionally substituted with xe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x, Rf, xe2x80x94C(O)Rf, or xe2x80x94C(O)xe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x;
R2 is hydrogen or a saccharide group optionally substituted with xe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x, Rf, xe2x80x94C(O)Rf, or xe2x80x94C(O)xe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x;
R3 is xe2x80x94ORc, xe2x80x94NRcRc, xe2x80x94Oxe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x, xe2x80x94NRcxe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x, xe2x80x94NRcRe, or xe2x80x94Oxe2x80x94Re; or R3 is a nitrogen-linked, oxygen-linked, or sulfur-linked substituent that comprises one or more phosphono groups;
R4 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, xe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x, xe2x80x94C(O)Rd and a saccharide group optionally substituted with xe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x, Rf, xe2x80x94C(O)Rf, or xe2x80x94C(O)xe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x, or R4 and R5 can be joined, together with the atoms to which they are attached, form a heterocyclic ring optionally substituted with xe2x80x94NRcxe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x;
R5 is selected from the group consisting of hydrogen, halo, xe2x80x94CH(Rc)xe2x80x94NRcRc, xe2x80x94CH(Rc)xe2x80x94NRcRe, xe2x80x94CH(Rc)xe2x80x94NRcxe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x, xe2x80x94CH(Rc)xe2x80x94Rx, xe2x80x94CH(Rc)xe2x80x94NRcxe2x80x94Raxe2x80x94C(xe2x95x90O)xe2x80x94Rx, and a substituent that comprises one or more phosphono groups;
R6 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, xe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x, xe2x80x94C(O)Rd and a saccharide group optionally substituted with xe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x, Rf, xe2x80x94C(O)Rf, or xe2x80x94C(O)xe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x, or R5 and R6 can be joined, together with the atoms to which they are attached, form a heterocyclic ring optionally substituted with xe2x80x94NRcxe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x;
R7 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, xe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x, and xe2x80x94C(O)Rd;
R8 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic;
R9 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic;
R10 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic; or R8 and R10 are joined to form xe2x80x94Ar1xe2x80x94Oxe2x80x94Ar2xe2x80x94, where Ar1 and Ar2 are independently arylene or heteroarylene;
R11 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic, or R10 and R11 are joined, together with the carbon and nitrogen atoms to which they are attached, to form a heterocyclic ring;
R12 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic, xe2x80x94C(O)Rd, xe2x80x94C(NH)Rd, xe2x80x94C(O)NRcRc, xe2x80x94C(O)ORd, xe2x80x94C(NH)NRcRc, xe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x, and xe2x80x94C(O)xe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x, or R11 and R12 are joined, together with the nitrogen atom to which they are attached, to form a heterocyclic ring;
R13 is selected from the group consisting of hydrogen or xe2x80x94OR14;
R14 is selected from hydrogen, xe2x80x94C(O)Rd and a saccharide group;
each Ra is independently selected from the group consisting of alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene and substituted alkynylene;
each Rb is independently selected from the group consisting of a covalent bond, alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene and substituted alkynylene, provided Rb is not a covalent bond when Z is hydrogen;
each Rc is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic and xe2x80x94C(O)Rd;
each Rd is independently selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic;
Re is a saccharide group;
each Rf is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, or heterocyclic;
Rx is an N-linked amino saccharide or an N-linked heterocycle;
X1, X2 and X3 are independently selected from hydrogen or chloro;
each Y is independently selected from the group consisting of oxygen, sulfur, xe2x80x94Sxe2x80x94Sxe2x80x94, xe2x80x94NRcxe2x80x94, xe2x80x94S(O)xe2x80x94, xe2x80x94SO2xe2x80x94, xe2x80x94NRcC(O)xe2x80x94, xe2x80x94OSO2xe2x80x94, xe2x80x94OC(O)xe2x80x94, xe2x80x94NRcSO2xe2x80x94, xe2x80x94C(O)NRcxe2x80x94, xe2x80x94C(O)Oxe2x80x94, xe2x80x94SO2NRcxe2x80x94, xe2x80x94SO2Oxe2x80x94, xe2x80x94P(O)(ORc)Oxe2x80x94, xe2x80x94P(O)(ORc)NRcxe2x80x94, xe2x80x94OP(O)(ORc)Oxe2x80x94, xe2x80x94OP(O)(ORc)NRcxe2x80x94, xe2x80x94OC(O)Oxe2x80x94, xe2x80x94NRcC(O)Oxe2x80x94, xe2x80x94NRcC(O)NRcxe2x80x94, xe2x80x94OC(O)NRcxe2x80x94, xe2x80x94C(xe2x95x90O)xe2x80x94, and xe2x80x94NRcSO2NRcxe2x80x94;
each Z is independently selected from hydrogen, aryl, cycloalkyl, cycloalkenyl, heteroaryl and heterocyclic;
n is 0, 1 or 2; and
x is 1 or 2;
or a pharmaceutically acceptable salt, stereoisomer, or prodrug thereof;
provided at least one of R3 and R5 is a substituent comprising one or more phosphono groups.
A preferred compound of the invention is a compound of formula I wherein: R1 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic and xe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x; or R1 is a saccharide group optionally substituted with xe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x, Rf, xe2x80x94C(O)Rf, or xe2x80x94C(O)xe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x; R2 is hydrogen or a saccharide group optionally substituted with xe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x, Rf, xe2x80x94C(O)Rf, or xe2x80x94C(O)xe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x; R3 is xe2x80x94ORc, xe2x80x94NRcRc, xe2x80x94Oxe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x, xe2x80x94NRcxe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x, xe2x80x94NRcRe, or xe2x80x94Oxe2x80x94Re; or R3 is a nitrogen-linked, oxygen-linked, or sulfur-linked substituent that comprises one or more phosphono groups; R4 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, xe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x, xe2x80x94C(O)Rd and a saccharide group optionally substituted with xe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x, Rf, xe2x80x94C(O)Rf, or xe2x80x94C(O)xe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x; R5 is selected from the group consisting of hydrogen, halo, xe2x80x94CH(Rc)xe2x80x94NRcRc, xe2x80x94CH(Rc)xe2x80x94NRcRe, xe2x80x94CH(Rc)xe2x80x94NRcxe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x, xe2x80x94CH(Rc)xe2x80x94Rx, xe2x80x94CH(Rc)xe2x80x94NRcxe2x80x94Raxe2x80x94C(xe2x95x90O)xe2x80x94Rx, and a substituent that comprises one or more phosphono groups; R6 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, xe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x, xe2x80x94C(O)Rd and a saccharide group optionally substituted with xe2x80x94NRcxe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x, or R5 and R6 can be joined, together with the atoms to which they are attached, form a heterocyclic ring optionally substituted with xe2x80x94NRcxe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x; R7 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, xe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x, and xe2x80x94C(O)Rd; R8 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic; R9 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic; R10 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic; or R8 and R10 are joined to form xe2x80x94Ar1xe2x80x94Oxe2x80x94Ar2xe2x80x94, where Ar1 and Ar2 are independently arylene or heteroarylene; R11 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic, or R10 and R11 are joined, together with the carbon and nitrogen atoms to which they are attached, to form a heterocyclic ring; R12 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic, xe2x80x94C(O)Rd, xe2x80x94C(NH)Rd, xe2x80x94C(O)NRcRc, xe2x80x94C(O)ORd, xe2x80x94C(NH)NRcRc and xe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x, or R11 and R12 are joined, together with the nitrogen atom to which they are attached, to form a heterocyclic ring; R13 is selected from the group consisting of hydrogen or xe2x80x94OR14; R14 is selected from hydrogen, xe2x80x94C(O)Rd and a saccharide group; each Ra is independently selected from the group consisting of alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene and substituted alkynylene; each Rb is independently selected from the group consisting of a covalent bond, alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene and substituted alkynylene, provided Rb is not a covalent bond when Z is hydrogen; each Rc is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic and xe2x80x94C(O)Rd; each Rd is independently selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic; Re is a saccharide group; each Rf is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, or heterocyclic; Rx is an N-linked amino saccharide or an N-linked heterocycle; X1, X2 and X3 are independently selected from hydrogen or chloro; each Y is independently selected from the group consisting of oxygen, sulfur, xe2x80x94Sxe2x80x94Sxe2x80x94, xe2x80x94NRcxe2x80x94, xe2x80x94S(O)xe2x80x94, xe2x80x94SO2xe2x80x94, xe2x80x94NRcC(O)xe2x80x94, xe2x80x94OSO2xe2x80x94, xe2x80x94OC(O)xe2x80x94, xe2x80x94NRcSO2xe2x80x94, xe2x80x94C(O)NRcxe2x80x94, xe2x80x94C(O)Oxe2x80x94, xe2x80x94SO2NRcxe2x80x94, xe2x80x94SO2Oxe2x80x94, xe2x80x94P(O)(ORc)Oxe2x80x94, xe2x80x94P(O)(ORc)NRcxe2x80x94, xe2x80x94OP(O)(ORc)Oxe2x80x94, xe2x80x94OP(O)(ORc)NRcxe2x80x94, xe2x80x94OC(O)Oxe2x80x94, xe2x80x94NRcC(O)Oxe2x80x94, xe2x80x94NRcC(O)NRcxe2x80x94, xe2x80x94OC(O)NRcxe2x80x94, xe2x80x94C(xe2x95x90O)xe2x80x94, and xe2x80x94NRcSO2NRcxe2x80x94; each Z is independently selected from hydrogen, aryl, cycloalkyl, cycloalkenyl, heteroaryl and heterocyclic; n is 0, 1 or 2; and x is 1 or 2; or a pharmaceutically acceptable salt, stereoisomer, or prodrug thereof; provided at least one of R3 and R5 is a substituent comprising one or more phosphono groups.
Preferably, R1 is a saccharide group optionally substituted with xe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x, Rf, xe2x80x94C(O)Rf, or xe2x80x94C(O)xe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z). More preferably R1 is a saccharide group substituted on the saccharide nitrogen with xe2x80x94CH2CH2xe2x80x94NHxe2x80x94(CH2)9CH3; xe2x80x94CH2CH2CH2xe2x80x94NHxe2x80x94(CH2)8CH3; xe2x80x94CH2CH2CH2CH2xe2x80x94NHxe2x80x94(CH2)7CH3; xe2x80x94CH2CH2xe2x80x94NHSO2xe2x80x94(CH2)9CH3; xe2x80x94CH2CH2xe2x80x94NHSO2xe2x80x94(CH2)11CH3; xe2x80x94CH2CH2xe2x80x94Sxe2x80x94(CH2)8CH3; xe2x80x94CH2CH2xe2x80x94Sxe2x80x94(CH2)9CH3; xe2x80x94CH2CH2xe2x80x94Sxe2x80x94(CH2)10CH3; xe2x80x94CH2CH2CH2xe2x80x94Sxe2x80x94(CH2)8CH3; xe2x80x94CH2CH2CH2xe2x80x94Sxe2x80x94(CH2)9CH3; xe2x80x94CH2CH2CH2xe2x80x94Sxe2x80x94(CH2)3xe2x80x94CHxe2x95x90CHxe2x80x94(CH2)4CH3 (trans); xe2x80x94CH2CH2CH2CH2xe2x80x94Sxe2x80x94(CH2)7CH3; xe2x80x94CH2CH2xe2x80x94S(O)xe2x80x94(CH2)9CH3; xe2x80x94CH2CH2xe2x80x94Sxe2x80x94(CH2)6Ph; xe2x80x94CH2CH2xe2x80x94Sxe2x80x94(CH2)8Ph; xe2x80x94CH2CH2CH2xe2x80x94Sxe2x80x94(CH2)8Ph; xe2x80x94CH2CH2xe2x80x94NHxe2x80x94CH2-4-(4-Clxe2x80x94Ph)xe2x80x94Ph; xe2x80x94CH2CH2xe2x80x94NHxe2x80x94CH2-4-[4-(CH3)2CHCH2xe2x80x94]xe2x80x94Ph; xe2x80x94CH2CH2xe2x80x94NHxe2x80x94CH2-4-(4-CF3xe2x80x94Ph)xe2x80x94Ph; xe2x80x94CH2CH2xe2x80x94Sxe2x80x94CH2-4-(4-Clxe2x80x94Ph)xe2x80x94Ph; xe2x80x94CH2CH2xe2x80x94S(O)xe2x80x94CH2-4-(4-Clxe2x80x94Ph)-Ph; xe2x80x94CH2CH2CH2xe2x80x94Sxe2x80x94CH2-4-(4-Clxe2x80x94Ph)xe2x80x94Ph; xe2x80x94CH2CH2CH2xe2x80x94S(O)xe2x80x94CH2-4-(4-Clxe2x80x94Ph)xe2x80x94Ph; xe2x80x94CH2CH2CH2xe2x80x94Sxe2x80x94CH2-4-[3,4-di-Clxe2x80x94PhCH2Oxe2x80x94)xe2x80x94Ph; xe2x80x94CH2CH2xe2x80x94NHSO2xe2x80x94CH2-4-[4-(4-Ph)xe2x80x94Ph]xe2x80x94Ph; xe2x80x94CH2CH2CH2xe2x80x94NHSO2xe2x80x94CH2-4-(4-Clxe2x80x94Ph)xe2x80x94Ph; xe2x80x94CH2CH2CH2xe2x80x94NHSO2xe2x80x94CH2-4-(Phxe2x80x94Cxe2x89xa1Cxe2x80x94)xe2x80x94Ph; xe2x80x94CH2CH2CH2xe2x80x94NHSO2-4(4-Clxe2x80x94Ph)xe2x80x94Ph; or xe2x80x94CH2CH2CH2xe2x80x94NHSO2-4-(naphth-2-yl)xe2x80x94Ph. Preferably R1 is also a saccharide group substituted on the saccharide nitrogen with a 4-(4-chlorophenyl)benzyl group or with a 4-(4-chlorobenzyloxy)benzyl group.
In a preferred embodiment, R1 is a saccharide group of the formula: 
wherein R15 is xe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x, Rf, xe2x80x94C(O)Rf, or xe2x80x94C(O)xe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x; and R16 is hydrogen or methyl.
Preferably, R15 is xe2x80x94CH2CH2xe2x80x94NHxe2x80x94(CH2)9CH3; xe2x80x94CH2CH2CH2xe2x80x94NHxe2x80x94(CH2)8CH3; xe2x80x94CH2CH2CH2CH2xe2x80x94NHxe2x80x94(CH2)7CH3; xe2x80x94CH2CH2xe2x80x94NHSO2xe2x80x94(CH2)9CH3; xe2x80x94CH2CH2xe2x80x94NHSO2xe2x80x94(CH2)11CH3; xe2x80x94CH2CH2xe2x80x94Sxe2x80x94(CH2)8CH3; xe2x80x94CH2CH2xe2x80x94Sxe2x80x94(CH2)9CH3; xe2x80x94CH2CH2xe2x80x94Sxe2x80x94(CH2)10CH3; xe2x80x94CH2CH2CH2xe2x80x94Sxe2x80x94(CH2)8CH3; xe2x80x94CH2CH2CH2xe2x80x94Sxe2x80x94(CH2)9CH3; xe2x80x94CH2CH2CH2xe2x80x94Sxe2x80x94(CH2)3xe2x80x94CHxe2x95x90CHxe2x80x94(CH2)4CH3 (trans); xe2x80x94CH2CH2CH2CH2xe2x80x94Sxe2x80x94(CH2)7CH3; xe2x80x94CH2CH2xe2x80x94S(O)xe2x80x94(CH2)9CH3; xe2x80x94CH2CH2xe2x80x94Sxe2x80x94(CH2)6Ph; xe2x80x94CH2CH2xe2x80x94(CH2)8Ph; xe2x80x94CH2CH2CH2xe2x80x94Sxe2x80x94(CH2)8Ph; xe2x80x94CH2CH2xe2x80x94NHxe2x80x94CH2-4-(4-Clxe2x80x94Ph)xe2x80x94Ph; xe2x80x94CH2CH2xe2x80x94NHxe2x80x94CH2-4-[4-(CH3)2CHCH2xe2x80x94]xe2x80x94Ph; xe2x80x94CH2CH2xe2x80x94NHxe2x80x94CH2-4-(4-CF3-Ph)xe2x80x94Ph; xe2x80x94CH2CH2xe2x80x94Sxe2x80x94CH2-4-(4-Clxe2x80x94Ph)xe2x80x94Ph; xe2x80x94CH2CH2xe2x80x94S(O)xe2x80x94CH2-4-(4-Clxe2x80x94Ph)xe2x80x94Ph; xe2x80x94CH2CH2CH2xe2x80x94Sxe2x80x94CH2-4-(4-Clxe2x80x94Ph)xe2x80x94Ph; xe2x80x94CH2CH2CH2xe2x80x94S(O)xe2x80x94CH2-4-(4-Clxe2x80x94Ph)xe2x80x94Ph; xe2x80x94CH2CH2CH2xe2x80x94Sxe2x80x94CH2-4-[3,4-di-Clxe2x80x94PhCH2Oxe2x80x94)xe2x80x94Ph; xe2x80x94CH2CH2xe2x80x94NHSO2xe2x80x94CH2-4-[4-(4-Ph)xe2x80x94Ph]xe2x80x94Ph; xe2x80x94CH2CH2CH2xe2x80x94NHSO2xe2x80x94CH2-4-(4-Clxe2x80x94Ph)xe2x80x94Ph; xe2x80x94CH2CH2CH2xe2x80x94NHSO2xe2x80x94CH2-4-(Ph-Cxe2x89xa1Cxe2x80x94)xe2x80x94Ph; xe2x80x94CH2CH2CH2xe2x80x94NHSO2-4-(4-Clxe2x80x94Ph)xe2x80x94Ph; or xe2x80x94CH2CH2CH2xe2x80x94NHSO2-4-(naphth-2-yl)xe2x80x94Ph. Preferably R15 can also be a 4-(4-chlorophenyl)benzyl group or a 4-(4-chlorobenzyloxy)benzyl group.
Preferably, R2 is hydrogen.
Preferably, R3 is xe2x80x94ORc; xe2x80x94NRcRc; or a nitrogen-linked, oxygen-linked, or sulfur-linked substituent comprising one or two phosphono groups, or a pharmaceutically acceptable salt thereof. When R3 is a phosphono-containing substituent, R3 is preferably a nitrogen-linked substituent comprising one phosphono group, or a pharmaceutically acceptable salt thereof. Preferably, R3 is a group of the formula xe2x80x94Oxe2x80x94Raxe2x80x94P(O)(OH)2, xe2x80x94Sxe2x80x94Raxe2x80x94P(O)(OH)2, or xe2x80x94NRcxe2x80x94Raxe2x80x94P(O)(OH)2. More preferably, R3 is a group of the formula xe2x80x94NHxe2x80x94Raxe2x80x94P(O)(OH)2, where Ra is as defined herein. In this formula, Ra is preferably an alkylene group. Particularly preferred R3 substituents include phosphonomethylamino, 3-phosphonopropylamino and 2-hydroxy-2-phosphonoethylamino groups and the like.
Preferably, when R3 is not a phosphono-containing substituent, R3 is xe2x80x94OH; xe2x80x94NHxe2x80x94(CH2)3xe2x80x94N(CH3)2; N-(D-glucosamine); xe2x80x94NHCH(CO2CH3)CH2CO2CH3; xe2x80x94NH(CH2)3xe2x80x94(morpholin-4-yl); xe2x80x94NH(CH2)3xe2x80x94NH(CH2)2CH3; xe2x80x94NH(CH2-piperidin-1-yl; xe2x80x94NH(CH2)4NHC(N)NH2; xe2x80x94NH(CH2)2xe2x80x94N+(CH3)3; xe2x80x94NHCH(COOH)(CH2)3NHC/]N)NH2; xe2x80x94NHxe2x80x94[CH2CH2CH2xe2x80x94NHxe2x80x94]3xe2x80x94H; xe2x80x94N[(CH2)3N(CH3)2]2; xe2x80x94NH(CH2)3-imidazol-1-yl; xe2x80x94NHCH2-4-pyridyl; xe2x80x94NH(CH2)3CH3; xe2x80x94NH(CH2)2OH; xe2x80x94NH(CH2)5OH; xe2x80x94NH(CH2)2OCH3; xe2x80x94NHCH2xe2x80x94-tetrahydrofuran-2-yl; xe2x80x94N[(CH2)2OH]2; xe2x80x94NH(CH2)2N[(CH2)2OH]2; xe2x80x94xe2x80x94NHCH2COOH; xe2x80x94NHCH(COOH)CH2OH; xe2x80x94NH(CH2)2COOH; N-(glucamine); xe2x80x94NH(CH2)2COOH; xe2x80x94NH(CH2)3SO3H; xe2x80x94NHCH(COOH)(CH2)2NH2; xe2x80x94NHCH(COOH)(CH2)3NH2; xe2x80x94NHCH(COOH)CH2CO2(CH2)3xe2x80x94N+(CH3)3; xe2x80x94NHCH(COOH)CH2CO2(CH2)2C(O)xe2x80x94N(CH3)2; xe2x80x94NHCH(COOH)CH2CO2(CH2)3-morpholin-4-yl; xe2x80x94NHCH(COOH)CH2CO2(CH2)2OC(O)C(CH3)3; xe2x80x94NHCH(CH2COOH)CO2(CH2)3xe2x80x94N+(CH3)3; xe2x80x94NHCH(CH2COOH)CO2(CH2)2C(O)N(CH3)2; or xe2x80x94NHCH(CH2COOH)CO2(CH2)3-morpholin-4-yl. xe2x80x94NHCH(CH2COOH)CO2(CH2)2OC(O)C(CH3)3; xe2x80x94NHCH(COOH)CH2CO2CH3; xe2x80x94NHCH(CH2COOH)CO2(CH2)2N(CH3)2; xe2x80x94NHCH(COOH)CH2CO2CH2C(O)N(CH3)2; xe2x80x94NHCH(CH2COOH)CO2CH2C(O)N(CH3)2; xe2x80x94NHCH(CH2COOH)CO2CH3; xe2x80x94NH(CH2)3N(CH3)2; xe2x80x94NHCH2CH2CO2CH3; xe2x80x94NHCH[CH2CO2CH2C(O)N(CH3)2]CO2CH2xe2x80x94C(O)xe2x80x94N(CH3)2; xe2x80x94NHCH2CO2CH3; xe2x80x94N-(methyl 3-amino-3-deoxyaminopyranoside); -N-(methyl 3-amino-2,3,6-trideoxyhexopyranoside); -N-(2-amino-2-deoxy-6-(dihydrogenphosphate)glucopyranose; xe2x80x94N-(2-amino-2-deoxygluconic acid); xe2x80x94NH(CH2)4COOH; xe2x80x94Nxe2x80x94(Nxe2x80x94CH3-D-glucamine; xe2x80x94NH(CH2)6COOH; xe2x80x94O(D-glucose); xe2x80x94NH(CH2)3OC(O)CH(NH2)CH3; xe2x80x94NH(CH2)4CH(C(O)-2-HOOC-pyrrolidin-1-yl)NHCH(COOH)xe2x80x94CH2CH2Ph (S,S isomer); xe2x80x94NHxe2x80x94CH2CH2xe2x80x94NHxe2x80x94(CH2)9CH3; xe2x80x94NH(CH2)C(O)CH2C(O)N(CH3)2;
Preferably, R4, R6 and R7 are each independently selected from hydrogen or xe2x80x94C(O)Rd. More preferably, R4, R6 and R7 are each hydrogen.
Preferably, R5 is hydrogen, xe2x80x94CH2xe2x80x94NHRc, xe2x80x94CH2xe2x80x94NRcRe, xe2x80x94CH2xe2x80x94NHxe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x, or a substituent comprising one or two phosphono groups. When R5 is a substituent comprising a phosphono group, R5 is preferably a group of the formula xe2x80x94CH(R21)xe2x80x94N(Rc)xe2x80x94Raxe2x80x94P(O)(OH)2 wherein R21 is hydrogen or Rd, preferably hydrogen, and Ra, Rc, and Rd, are as defined herein. More preferably, when R5 is phosphono-containing substituent, R5 is preferably a group of the formula xe2x80x94CH2xe2x80x94NHxe2x80x94Raxe2x80x94P(O)(OH)2, where Ra is as defined herein. In this formula, Ra is preferably an alkylene group; more preferably, an alkylene group containing from 2 to about 6 carbon atoms.
Particularly preferred R5 substituents include N-(phosphonomethyl)-aminomethyl; N-(2-hydroxy-2-phosphonoethyl)aminomethyl; N-carboxymethyl-N-(2-phosphonoethyl)aminomethyl; N,N-bis(phosphonomethyl)-aminomethyl; and N-(3-phosphonopropyl)aminomethyl; and the like.
Preferably, when R5 is not a phosphono-containing Substituent, R5 is hydrogen, xe2x80x94CH2xe2x80x94NHRc, xe2x80x94CH2xe2x80x94NRcRexe2x80x94 or xe2x80x94CH2xe2x80x94NHxe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x, R5 can also preferably be hydrogen; xe2x80x94CH2xe2x80x94Nxe2x80x94(Nxe2x80x94CH3-D-glucamine); xe2x80x94CH2xe2x80x94NHxe2x80x94CH2CH2xe2x80x94NHxe2x80x94(CH2)9CH3; xe2x80x94CH2xe2x80x94NHxe2x80x94CH2CH2xe2x80x94NHC(O)xe2x80x94(CH2)3COOH; xe2x80x94CH2xe2x80x94NHxe2x80x94(CH2)9CH3;xe2x80x94CH2xe2x80x94NHxe2x80x94CH2CH2xe2x80x94COOH; xe2x80x94CH2xe2x80x94NHxe2x80x94(CH2)5COOH; xe2x80x94CH2-(morpholin-4-yl); xe2x80x94CH2xe2x80x94NHxe2x80x94CH2CH2xe2x80x94Oxe2x80x94CH2OH; xe2x80x94CH2xe2x80x94NHxe2x80x94CH2CH(OH)xe2x80x94CH2OH; xe2x80x94CH2xe2x80x94N[CH2CH2OH]2; xe2x80x94CH2xe2x80x94NHxe2x80x94(CH2)3xe2x80x94N(CH3)2; xe2x80x94CH2xe2x80x94N[(CH2)3xe2x80x94N(CH3)2]2; xe2x80x94CH2xe2x80x94NHxe2x80x94(CH2)3-(imidazol-1-yl); xe2x80x94CH2xe2x80x94NHxe2x80x94(CH2)3xe2x80x94(morpholin-4-yl); xe2x80x94CH2xe2x80x94NHxe2x80x94(CH2)4xe2x80x94NHC(NH)NH2; xe2x80x94CH2xe2x80x94Nxe2x80x94(2-amino-2-deoxygluconic acid);xe2x80x94CH2xe2x80x94NHxe2x80x94CH2CH2xe2x80x94NHxe2x80x94(CH2)11CH3; xe2x80x94CH2xe2x80x94NHxe2x80x94CH(COOH)CH2COOH; xe2x80x94CH2xe2x80x94NHxe2x80x94CH2CH2xe2x80x94NHSO2xe2x80x94(CH2)7CH3; xe2x80x94CH2xe2x80x94NHxe2x80x94CH2CH2xe2x80x94NHSO2xe2x80x94(CH2)8CH3; CH2xe2x80x94NHxe2x80x94CH2CH2xe2x80x94NHSO2xe2x80x94(CH2)9CH3; xe2x80x94CH2xe2x80x94NHxe2x80x94CH2CH2xe2x80x94NHSO2xe2x80x94(CH2)3; xe2x80x94CH3; xe2x80x94CH2xe2x80x94NHxe2x80x9411CH3; xe2x80x94CH2xe2x80x94NHxe2x80x94CH2CH2xe2x80x94NHxe2x80x94(CH2)7CH3; xe2x80x94CH2xe2x80x94NHxe2x80x94CH2CH2xe2x80x94Oxe2x80x94CH2 CH2OH; xe2x80x94CH2xe2x80x94NHxe2x80x94CH2CH2C(O)xe2x80x94N-(D-glucosamine); xe2x80x94CH2xe2x80x94NHxe2x80x94(6-oxo-[1,3]oxazinan-3-yl); xe2x80x94CH2xe2x80x94NHxe2x80x94CH2CH2xe2x80x94Sxe2x80x94(CH2)7CH3; xe2x80x94CH2xe2x80x94NHxe2x80x94CH2CH2xe2x80x94Sxe2x80x94(CH2)8CH3; xe2x80x94CH2xe2x80x94NHxe2x80x94CH2xe2x80x94Sxe2x80x94(CH2)9CH3; xe2x80x94CH2xe2x80x94NHxe2x80x94CH2CH2xe2x80x94Sxe2x80x94(CH2)11CH3; xe2x80x94CH2xe2x80x94NHxe2x80x94CH2CH2xe2x80x94Sxe2x80x94(CH2)6Ph; xe2x80x94CH2xe2x80x94NHxe2x80x94CH2CH2xe2x80x94Sxe2x80x94(CH2)8Ph; xe2x80x94CH2xe2x80x94NHxe2x80x94CH2CH2xe2x80x94Sxe2x80x94(CH2)10Ph; xe2x80x94CH2xe2x80x94NHxe2x80x94CH2CH2xe2x80x94Sxe2x80x94CH2xe2x80x94(4-(4-(CF3xe2x80x94Ph)Ph); xe2x80x94CH2xe2x80x94NHxe2x80x94CH2CH2xe2x80x94NHxe2x80x94(CH2)11CH3; or xe2x80x94CH2xe2x80x94NHxe2x80x94(CH2)5xe2x80x94COOH.
Preferably, R8 is xe2x80x94CH2C(O)NH2, xe2x80x94CH2COOH, benzyl, 4-hydroxyphenyl or 3-chloro-4-hydroxyphenyl.
Preferably, R9 is hydrogen or alkyl.
Preferably, R10 is alkyl or substituted alkyl. More preferably, R10 is the side-chain of a naturally occurring amino acid, such as isobutyl.
Preferably, R11 is hydrogen or alkyl.
Preferably, R12 is hydrogen, alkyl, substituted alkyl or xe2x80x94C(O)Rd. R12 can also preferably be hydrogen; xe2x80x94CH2COOH; xe2x80x94CH2xe2x80x94[CH(OH)]5CH2OH; xe2x80x94CH2CH(OH)CH2OH; xe2x80x94CH2CH2NH2; xe2x80x94CH2C(O)OCH2CH3; xe2x80x94CH2-(2-pyridyl); xe2x80x94CH2-[CH(OH)]4COOH; xe2x80x94CH2; (3xe2x80x94carboxyphenyl); (R)xe2x80x94C(O)CH(NH2)(CH2)4NH2; xe2x80x94C(O)Ph; xe2x80x94C(O)CH2NHC(O)CH3; Exe2x80x94CH2CH2xe2x80x94Sxe2x80x94(CH2)3CHxe2x95x90CH(CH2)4CH3; or xe2x80x94C(O)CH3.
Preferably, X1 and X2 are each chloro.
Preferably, X3 is hydrogen.
Preferably, each Y is independently selected from the group consisting of oxygen, sulfur, xe2x80x94Sxe2x80x94Sxe2x80x94, xe2x80x94NRcxe2x80x94, xe2x80x94S(O)xe2x80x94, xe2x80x94SO2xe2x80x94, xe2x80x94NRcC(O)xe2x80x94, xe2x80x94OSO2xe2x80x94, xe2x80x94OC(O)xe2x80x94, xe2x80x94NRcSO2xe2x80x94, xe2x80x94C(O)NRcxe2x80x94, xe2x80x94C(O)Oxe2x80x94, xe2x80x94SO2NRcxe2x80x94, xe2x80x94SO2Oxe2x80x94, xe2x80x94P(O)(ORc)Oxe2x80x94, xe2x80x94P(O)(ORc)NRcxe2x80x94, xe2x80x94OP(O)(ORc)Oxe2x80x94, xe2x80x94OP(O)(ORc)NRcxe2x80x94, xe2x80x94OC(O)Oxe2x80x94, xe2x80x94NRcC(O)Oxe2x80x94, xe2x80x94NRcC(O)NRcxe2x80x94, xe2x80x94OC(O)NRcxe2x80x94, and xe2x80x94NRcSO2NRcxe2x80x94.
Preferably, n is 0 or 1, and more preferably, n is 1.
Another preferred compound of the invention is a glycopeptide of formula II: 
wherein:
R19 is hydrogen;
R20 is xe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x, Rf, xe2x80x94C(O)Rf, or xe2x80x94C(O)xe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x; and
Ra, Y, Rb, Z, x, Rf, R3, and R5 have any of the values or preferred values described herein;
or a pharmaceutically acceptable salt, stereoisomer, or prodrug thereof,
provided at least one of R3 and R5 is a substituent comprising one or more phosphono groups.
Preferably, R20 is xe2x80x94CH2CH2xe2x80x94NHxe2x80x94(CH2)9CH3; xe2x80x94CH2CH2CH2xe2x80x94NHxe2x80x94(CH2)8CH3; xe2x80x94CH2CH2CH2CH2xe2x80x94NHxe2x80x94(CH2)7CH3; xe2x80x94CH2CH2xe2x80x94NHSO2xe2x80x94(CH2)9CH3; xe2x80x94CH2CH2xe2x80x94NHSO2xe2x80x94(CH2)11CH3; xe2x80x94CH2CH2xe2x80x94Sxe2x80x94(CH2)8CH3; xe2x80x94CH2CH2xe2x80x94Sxe2x80x94(CH2)9CH3; xe2x80x94CH2xe2x80x94Sxe2x80x94(CH2)10CH3; xe2x80x94CH2CH2CH2xe2x80x94Sxe2x80x94(CH2)8CH3; xe2x80x94CH2CH2CH2xe2x80x94Sxe2x80x94(CH2)9CH3; xe2x80x94CH2CH2CH2xe2x80x94Sxe2x80x94(CH2)3; CHxe2x95x90CHxe2x80x94(CH2)4CH3 (trans); xe2x80x94CH2CH2CH2CH2xe2x80x94Sxe2x80x94(CH2)7CH3; xe2x80x94CH2CH2xe2x80x94S(O)xe2x80x94(CH2)9CH3; xe2x80x94CH2CH2xe2x80x94Sxe2x80x94(CH2)6Ph; xe2x80x94CH2CH2xe2x80x94Sxe2x80x94(CH2)8Ph; xe2x80x94CH2CH2CH2xe2x80x94Sxe2x80x94(CH2)8Ph; xe2x80x94CH2CH2xe2x80x94NHxe2x80x94CH2-4-(4-Clxe2x80x94Ph)xe2x80x94Ph; xe2x80x94CH2CH2xe2x80x94NHxe2x80x94CH2-4-[4-(CH3)2CHCH2xe2x80x94]xe2x80x94Ph; xe2x80x94CH2CH2xe2x80x94NHxe2x80x94CH2-4-(4-CF3xe2x80x94Ph)xe2x80x94Ph; xe2x80x94CH2CH2xe2x80x94Sxe2x80x94CH2-4-(4-Clxe2x80x94Ph)xe2x80x94Ph; xe2x80x94CH2CH2xe2x80x94S(O)xe2x80x94CH2-4-(4-Clxe2x80x94Ph)xe2x80x94Ph; xe2x80x94CH2CH2CH2xe2x80x94Sxe2x80x94CH2-4-(4-Clxe2x80x94Ph)xe2x80x94Ph; xe2x80x94CH2CH2CH2xe2x80x94S(O)xe2x80x94CH2-4-(4Clxe2x80x94Ph)xe2x80x94Ph; xe2x80x94CH2CH2CH2xe2x80x94Sxe2x80x94CH2-4-[3,4-di-Clxe2x80x94PhCH2Oxe2x80x94)xe2x80x94Ph; xe2x80x94CH2CH2xe2x80x94NHSO2xe2x80x94CH2-4-[4-(4-Ph)xe2x80x94Ph]xe2x80x94Ph; xe2x80x94CH2CH2CH2xe2x80x94NHSO2xe2x80x94CH2-4-(4-Clxe2x80x94Ph)xe2x80x94Ph; xe2x80x94CH2CH2CH2xe2x80x94NHSO2xe2x80x94CH2-4-(Phxe2x80x94Cxe2x89xa1Cxe2x80x94)xe2x80x94Ph; xe2x80x94CH2CH2CH2xe2x80x94NHSO2-4-(4-Clxe2x80x94Ph)xe2x80x94Ph; or xe2x80x94CH2CH2CH2xe2x80x94NHSO2-4-(naphth-2-yl)xe2x80x94Ph. Preferably R20 is also a 4-(4-chlorophenyl)benzyl group or a 4-(4-chlorobenzyloxy)benzyl group.
In another preferred embodiment, the invention provides a compound of formula II, wherein R19 is hydrogen; R20 is xe2x80x94CH2CH2NHxe2x80x94(CH2)9CH3; R3 is xe2x80x94OH; and 5 is a substituent comprising a phosphono group; or a pharmaceutically acceptable salt thereof.
In yet another preferred embodiment, the invention provides a compound of formula II, wherein R19 is hydrogen; R20 is xe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x, Rf, xe2x80x94C(O)Rf, or xe2x80x94C(O)xe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x; R3 is xe2x80x94OH; and R5 is xe2x80x94CH2xe2x80x94NHxe2x80x94CH2xe2x80x94P(O)(OH)2; or a pharmaceutically acceptable salt thereof.
The invention also provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of the invention. In one preferred embodiment, the pharmaceutically acceptable carrier comprises an aqueous cyclodextrin solution. Preferably, the cyclodextrin is hydroxypropyl-xcex2-cyclodextrin or sulfobutyl ether xcex2-cyclodextrin. More preferably, the cyclodextrin is hydroxypropyl-xcex2-cyclodextrin.
The compounds of the invention are highly effective antibacterial agents. Accordingly, the invention also provides a method of treating a mammal having a bacterial disease, comprising administering to the mammal a therapeutically effective amount of a compound of the invention. The invention also provides a method of treating a mammal having a bacterial disease, comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition of the invention.
The invention also provides processes and intermediates useful for preparing compounds of the invention, which processes and intermediates are described further herein.
The invention also provides a compound of the invention as described herein for use in medical therapy, as well as the use of a compound of the invention in the manufacture of a formulation or medicament for treating a bacterial disease in a mammal.
The invention also provides a pharmaceutical composition which comprises as an active ingredient a compound of the invention for the treatment of a bacterial disease.
The invention also provides a method for preparing a glycopeptide of the invention which is substituted at the C-terminus with a substituent that comprises one or more phosphono groups, comprising coupling a corresponding starting glycopeptide wherein the C-terminus is a carboxy group with a suitable phosphono containing compound.
The invention also provides a method for preparing a glycopeptide of the invention which is substituted at the R-terminus with a substituent that comprises one or more phosphono groups, comprising coupling a corresponding starting glycopeptide wherein the R-terminus is unsubstituted with a suitable phosphono containing compound. When the starting glycopeptide is substituted at the vancosamine amino terminus, such a method can further optionally comprise preparing the starting glycopeptide by reductively alkylating a corresponding glycopeptide wherein the vancosamine amino terminus is the corresponding amine.
The invention also provides a method for preparing a glycopeptide of the invention that is substituted at the C-terminus, comprising derivatizing a corresponding starting glycopeptide wherein the C-terminus is a carboxy group.
The invention also provides a method for preparing a glycopeptide of the invention which is substituted at the R-terminus, comprising derivatizing a corresponding starting glycopeptide wherein the R-terminus is unsubstituted (i.e. a hydrogen).
This invention also provides a method for preparing a compound of formula II, wherein R3 is xe2x80x94OH, R5 is xe2x80x94CH2xe2x80x94NHxe2x80x94Raxe2x80x94P(O)(OH)2, R19 is hydrogen and R20 is xe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x, or xe2x80x94Rf, and Ra, Rb, Rf, Y, Z and x are as defined herein, or salt thereof; the method comprising:
(a) reductively alkylating a compound of formula II, wherein R3 is xe2x80x94OH and R5, R19 and R20 are hydrogen, or a salt thereof, with an aldehyde of the formula HC(O)xe2x80x94Raxe2x80x2xe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x, or HC(O)Rfxe2x80x2 wherein Raxe2x80x2 and Rfxe2x80x2 represent Ra and Rf, respectively, minus one xe2x80x94CH2xe2x80x94 group, to form a compound of formula II wherein R3 is xe2x80x94OH, R5 and R19 are hydrogen and R20 is xe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x or xe2x80x94Rf, or salt thereof, and
(b) reacting the product from step (a) with formaldehyde and H2Nxe2x80x94Raxe2x80x94P(O)(OH)2 to form a compound of formula II wherein R3 is xe2x80x94OH, R5 is xe2x80x94CH2NHxe2x80x94Raxe2x80x94P(O)(OH)2, R19 is hydrogen and R20 is xe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x, or xe2x80x94Rf, or salt thereof.
Preferred compounds of the invention are the compounds of formula II shown in Table I below wherein R19 is hydrogen.
Another preferred group of compounds of the invention are phosphono derivatives of the glycopeptide antibiotic A82846B (also known as chloroorienticin A oy LY264826). See for example R. Nagarajan et al., J. Org. Chem., 1988, 54, 983-986; and N. Tsuji et al., J. Antibiot., 1988, 41, 819-822. The structure of this glycopeptide is similar to vancomycin, except A82846B contains an additional amino sugar (i.e. 4-epivancosamine attached at the R2 position in formula I.) and further contains 4-epivancosamine in place of vancosamine in the disaccharide moiety attached at the R1 position in formula I. For example, a preferred group of compounds are N-alkylated derivatives of A82846B that are substituted at the C-terminus or the R-terminus with a substituent that comprises one or more (e.g. 1, 2, 3, 4, or 5) phosphono (xe2x80x94PO3H2) groups; or a pharmaceutically acceptable salt thereof. A preferred group of compounds of the invention that are derivatives of A82846B are substituted at either the C-terminus or the R-terminus with a substituent that comprises one or more (e.g. 1, 2, 3, 4, or 5) phosphono (xe2x80x94PO3H2) groups. Another preferred group of compounds of the invention that are derivatives of A82846B are substituted at the C-terminus and the R-terminus with substituents that each comprises one or more (e.g. 1, 2, 3, 4, or 5) phosphono (xe2x80x94PO3H2) groups. Another preferred group of compounds of the invention are phosphono derivatives of A82846B having a 4-(4-chlorophenyl)benzyl group or a 4-(4-chlorobenzyloxy)benzyl group attached at the amino group of the 4-epi-vancosamine of the disaccharide moiety. The compounds of the invention that are phosphono derivatives of A82846B can readily be prepared using the procedures described herein.
The phosphono compounds of the invention have been found to unexpectedly exhibit reduced tissue accumulation and/or nephrotoxicity when administered to a mammal. While not wishing to be bound by theory, it is believed that the phosphono moiety serves to increase the overall negative charge of the glycopeptide under physiological conditions thereby facilitating excretion from the mammal after administration. The unexpected increase in excretion of the phosphono compounds of the invention may be responsible for the reduced tissue accumulation and/or reduced nephrotoxicity observed for these compounds relative to the corresponding compounds that lack the phosphono functionality.
This invention relates to novel compounds of the invention, which are derivatives of glycopeptide antibiotics comprising one or more substituents that comprise one or more phosphono groups, as well as to compositions comprising such compounds and to therapeutic methods comprising the administration of such compounds. When describing the compounds, compositions and methods of the invention, the following terms have the following meanings, unless otherwise indicated.
The term xe2x80x9calkylxe2x80x9d refers to a monoradical branched or unbranched saturated hydrocarbon chain preferably having from 1 to 40 carbon atoms, more preferably 1 to 10 carbon atoms, and even more preferably 1 to 6 carbon atoms. This term is exemplified by groups such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, n-hexyl, n-decyl, tetradecyl, and the like.
The term xe2x80x9csubstituted alkylxe2x80x9d refers to an alkyl group as defined above, having from 1 to 8 substituents, preferably 1 to 5 substituents, and more preferably 1 to 3 substituents, selected from the group consisting of alkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl, keto, thioketo, carboxy, carboxyalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclic, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, xe2x80x94SO-alkyl, xe2x80x94SO-substituted alkyl, xe2x80x94SO-aryl, xe2x80x94SO-heteroaryl, xe2x80x94SO2-alkyl, xe2x80x94SO2-substituted alkyl, xe2x80x94SO2-aryl, xe2x80x94SO3H, guanido, and xe2x80x94SO2-heteroaryl.
The term xe2x80x9calkylenexe2x80x9d refers to a diradical of a branched or unbranched saturated hydrocarbon chain, preferably having from 1 to 40 carbon atoms, preferably 1-10 carbon atoms, more preferably 1-6 carbon atoms. This term is exemplified by groups such as methylene (xe2x80x94CH2xe2x80x94), ethylene (xe2x80x94CH2CH2xe2x80x94), the propylene isomers (e.g., xe2x80x94CH2CH2CH2xe2x80x94 and xe2x80x94CH(CH3)CH2xe2x80x94) and the like.
The term xe2x80x9csubstituted alkylenexe2x80x9d refers to an alkylene group, as defined above, having from 1 to 5 substituents, and preferably 1 to 3 substituents, selected from the group consisting of alkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl, carboxy, carboxyalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclic, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, xe2x80x94SO-alkyl, xe2x80x94SO-substituted alkyl, xe2x80x94SO-aryl, xe2x80x94SO-heteroaryl, xe2x80x94SO2-alkyl, xe2x80x94SO2-substituted alkyl, xe2x80x94SO2-aryl and xe2x80x94SO2-heteroaryl. Additionally, such substituted alkylene groups include those where 2 substituents on the alkylene group are fused to form one or more cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heterocyclic or heteroaryl groups fused to the alkylene group. Preferably such fused groups contain from 1 to 3 fused ring structures. Additionally, the term substituted alkylene includes alkylene groups in which from 1 to 5 of the alkylene carbon atoms are replaced with oxygen, sulfur or xe2x80x94NRxe2x80x94 where R is hydrogen or alkyl. Examples of substituted alkylenes are chloromethylene (xe2x80x94CH(Cl)xe2x80x94), aminoethylene (xe2x80x94CH(NH2)CH2xe2x80x94), 2-carboxypropylene isomers (xe2x80x94CH2CH(CO2H)CH2xe2x80x94), ethoxyethyl (xe2x80x94CH2CH2 Oxe2x80x94CH2CH2xe2x80x94) and the like.
The term xe2x80x9calkarylxe2x80x9d refers to the groups -alkylene-aryl and -substituted alkylene-aryl where alkylene, substituted alkylene and aryl are defined herein. Such alkaryl groups are exemplified by benzyl, phenethyl and the like.
The term xe2x80x9calkoxyxe2x80x9d refers to the groups alkyl-Oxe2x80x94, alkenyl-Oxe2x80x94, cycloalkyl-Oxe2x80x94, cycloalkenyl-Oxe2x80x94, and alkynyl-Oxe2x80x94, where alkyl, alkenyl, cycloalkyl, cycloalkenyl, and alkynyl are as defined herein. Preferred alkoxy groups are alkyl-Oxe2x80x94 and include, by way of example, methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, 1,2-dimethylbutoxy, and the like.
The term xe2x80x9csubstituted alkoxyxe2x80x9d refers to the groups substituted alkyl-Oxe2x80x94, substituted alkenyl-Oxe2x80x94, substituted cycloalkyl-Oxe2x80x94, substituted cycloalkenyl-Oxe2x80x94, and substituted alkynyl-Oxe2x80x94 where substituted alkyl, substituted alkenyl, substituted cycloalkyl, substituted cycloalkenyl and substituted alkynyl are as defined herein.
The term xe2x80x9calkylalkoxyxe2x80x9d refers to the groups -alkylene-O-alkyl, alkylene-O-substituted alkyl, substituted alkylene-O-alkyl and substituted alkylene-O-substituted alkyl wherein alkyl, substituted alkyl, alkylene and substituted alkylene are as defined herein. Preferred alkylalkoxy groups are alkylene-O-alkyl and include, by way of example, methylenemethoxy (xe2x80x94CH2OCH3), ethylenemethoxy (xe2x80x94CH2CH2OCH3), n-propylene-iso-propoxy (xe2x80x94CH2CH2CH2OCH(CH3)2), methylene-t-butoxy (xe2x80x94CH2xe2x80x94Oxe2x80x94C(CH3)3) and the like.
The term xe2x80x9calkylthioalkoxyxe2x80x9d refers to the group -alkylene-S-alkyl, alkylene-S-substituted alkyl, substituted alkylene-S-alkyl and substituted alkylene-S-substituted alkyl wherein alkyl, substituted alkyl, alkylene and substituted alkylene are as defined herein. Preferred alkylthioalkoxy groups are alkylene-S-alkyl and include, by way of example, methylenethiomethoxy (xe2x80x94CH2SCH3), ethylenethiomethoxy (xe2x80x94CH2CH2SCH3), n-propylene-iso-thiopropoxy (xe2x80x94CH2CH2CH2SCH(CH3)2), methylene-t-thiobutoxy (xe2x80x94CH2SC(CH3)3) and the like.
The term xe2x80x9calkenylxe2x80x9d refers to a monoradical of a branched or unbranched unsaturated hydrocarbon group preferably having from 2 to 40 carbon atoms, more preferably 2 to 10 carbon atoms and even more preferably 2 to 6 carbon atoms and having at least 1 and preferably from 1-6 sites of vinyl unsaturation. Preferred alkenyl groups include ethenyl (xe2x80x94CHxe2x95x90CH2), n-propenyl (xe2x80x94CH2CHxe2x95x90CH2), iso-propenyl (xe2x80x94C(CH3)xe2x95x90CH2), and the like.
The term xe2x80x9csubstituted alkenylxe2x80x9d refers to an alkenyl group as defined above having from 1 to 5 substituents, and preferably 1 to 3 substituents, selected from the group consisting of alkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl, keto, thioketo, carboxy, carboxyalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclic, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, xe2x80x94SO-alkyl, xe2x80x94SO-substituted alkyl, xe2x80x94SO-aryl, xe2x80x94SO-heteroaryl, xe2x80x94SO2-alkyl, xe2x80x94SO2-substituted alkyl, xe2x80x94SO2-aryl and xe2x80x94SO2-heteroaryl.
The term xe2x80x9calkenylenexe2x80x9d refers to a diradical of a branched or unbranched unsaturated hydrocarbon group preferably having from 2 to 40 carbon atoms, more preferably 2 to 10 carbon atoms and even more preferably 2 to 6 carbon atoms and having at least 1 and preferably from 1-6 sites of vinyl unsaturation. This term is exemplified by groups such as ethenylene (xe2x80x94CHxe2x95x90CHxe2x80x94), the propenylene isomers (e.g., xe2x80x94CH2CHxe2x95x90CHxe2x80x94 and xe2x80x94C(CH3)xe2x95x90CHxe2x80x94) and the like.
The term xe2x80x9csubstituted alkenylenexe2x80x9d refers to an alkenylene group as defined above having from 1 to 5 substituents, and preferably from 1 to 3 substituents, selected from the group consisting of alkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl, carboxy, carboxyalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclic, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, xe2x80x94SO-alkyl, xe2x80x94SO-substituted alkyl, xe2x80x94SO-aryl, xe2x80x94SO-heteroaryl, xe2x80x94SO2-alkyl, xe2x80x94SO2-substituted alkyl, xe2x80x94SO2-aryl and xe2x80x94SO2-heteroaryl. Additionally, such substituted alkenylene groups include those where 2 substituents on the alkenylene group are fused to form one or more cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heterocyclic or heteroaryl groups fused to the alkenylene group.
The term xe2x80x9calkynylxe2x80x9d refers to a monoradical of an unsaturated hydrocarbon preferably having from 2 to 40 carbon atoms, more preferably 2 to 20 carbon atoms and even more preferably 2 to 6 carbon atoms and having at least 1 and preferably from 1-6 sites of acetylene (triple bond) unsaturation. Preferred alkynyl groups include ethynyl (xe2x80x94Cxe2x89xa1CH), propargyl (xe2x80x94CH2Cxe2x89xa1CH) and the like.
The term xe2x80x9csubstituted alkynylxe2x80x9d refers to an alkynyl group as defined above having from 1 to 5 substituents, and preferably 1 to 3 substituents, selected from the group consisting of alkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl, carboxy, carboxyalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclic, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, xe2x80x94SO-alkyl, xe2x80x94SO-substituted alkyl, xe2x80x94SO-aryl, xe2x80x94SO-heteroaryl, xe2x80x94SO2-alkyl, xe2x80x94SO2-substituted alkyl, xe2x80x94SO2-aryl and xe2x80x94SO2-heteroaryl.
The term xe2x80x9calkynylenexe2x80x9d refers to a diradical of an unsaturated hydrocarbon preferably having from 2 to 40 carbon atoms, more preferably 2 to 10 carbon atoms and even more preferably 2 to 6 carbon atoms and having at least 1 and preferably from 1-6 sites of acetylene (triple bond) unsaturation. Preferred alkynylene groups include ethynylene (xe2x80x94Cxe2x89xa1Cxe2x80x94), propargylene (xe2x80x94CH2Cxe2x89xa1Cxe2x80x94) and the like.
The term xe2x80x9csubstituted alkynylenexe2x80x9d refers to an alkynylene group as defined above having from 1 to 5 substituents, and preferably 1 to 3 substituents, selected from the group consisting of alkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl, keto, thioketo, carboxy, carboxyalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclic, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, xe2x80x94SO-alkyl, xe2x80x94SO-substituted alkyl, xe2x80x94SO-aryl, xe2x80x94SO-heteroaryl, xe2x80x94SO2-alkyl, xe2x80x94SO2-substituted alkyl, xe2x80x94SO2-aryl and xe2x80x94SO2-heteroaryl.
The term xe2x80x9cacylxe2x80x9d refers to the groups HC(O)xe2x80x94, alkyl-C(O)xe2x80x94, substituted alkyl-C(O)xe2x80x94, cycloalkyl-C(O)xe2x80x94, substituted cycloalkyl-C(O)xe2x80x94, cycloalkenyl-C(O)xe2x80x94, substituted cycloalkenyl-C(O)xe2x80x94, aryl-C(O)xe2x80x94, heteroaryl-C(O)xe2x80x94 and heterocyclic-C(O)xe2x80x94 where alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic are as defined herein.
The term xe2x80x9cacylaminoxe2x80x9d or xe2x80x9caminocarbonylxe2x80x9d refers to the group xe2x80x94C(O)NRR where each R is independently hydrogen, alkyl, substituted alkyl, aryl, heteroaryl, heterocyclic or where both R groups are joined to form a heterocyclic group (e.g., morpholino) wherein alkyl, substituted alkyl, aryl, heteroaryl and heterocyclic are as defined herein.
The term xe2x80x9caminoacylxe2x80x9d refers to the group xe2x80x94NRC(O)R where each R is independently hydrogen, alkyl, substituted alkyl, aryl, heteroaryl, or heterocyclic wherein alkyl, substituted alkyl, aryl, heteroaryl and heterocyclic are as defined herein.
The term xe2x80x9caminoacyloxyxe2x80x9d or xe2x80x9calkoxycarbonylaminoxe2x80x9d refers to the group xe2x80x94NRC(O)OR where each R is independently hydrogen, alkyl, substituted alkyl, aryl, heteroaryl, or heterocyclic wherein alkyl, substituted alkyl, aryl, heteroaryl and heterocyclic are as defined herein.
The term xe2x80x9cacyloxyxe2x80x9d refers to the groups alkyl-C(O)Oxe2x80x94, substituted alkyl-C(O)Oxe2x80x94, cycloalkyl-C(O)Oxe2x80x94, substituted cycloalkyl-C(O)Oxe2x80x94, aryl-C(O)Oxe2x80x94, heteroaryl-C(O)Oxe2x80x94, and heterocyclic-C(O)Oxe2x80x94 wherein alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, heteroaryl, and heterocyclic are as defined herein.
The term xe2x80x9carylxe2x80x9d refers to an unsaturated aromatic carbocyclic group of from 6 to 20 carbon atoms having a single ring (e.g., phenyl) or multiple condensed (fused) rings, wherein at least one ring is aromatic (e.g., naphthyl, dihydrophenanthrenyl, fluorenyl, or anthryl). Preferred aryls include phenyl, naphthyl and the like.
Unless otherwise constrained by the definition for the aryl substituent, such aryl groups can optionally be substituted with from 1 to 5 substituents, preferably 1 to 3 substituents, selected from the group consisting of acyloxy, hydroxy, thiol, acyl, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, substituted alkyl, substituted alkoxy, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted cycloalkenyl, amino, substituted amino, aminoacyl, acylamino, alkaryl, aryl, aryloxy, azido, carboxy, carboxyalkyl, cyano, halo, nitro, heteroaryl, heteroaryloxy, heterocyclic, heterocyclooxy, aminoacyloxy, oxyacylamino, sulfonamide, thioalkoxy, substituted thioalkoxy, thioaryloxy, thioheteroaryloxy, xe2x80x94SO-alkyl, xe2x80x94SO-substituted alkyl, xe2x80x94SO-aryl, xe2x80x94SO-heteroaryl, xe2x80x94SO2-alkyl, xe2x80x94SO2-substituted alkyl, xe2x80x94SO2-aryl, xe2x80x94SO2-heteroaryl and trihalomethyl. Preferred aryl substituents include alkyl, alkoxy, halo, cyano, nitro, trihalomethyl, and thioalkoxy.
The term xe2x80x9caryloxyxe2x80x9d refers to the group aryl-Oxe2x80x94 wherein the aryl group is as defined above including optionally substituted aryl groups as also defined above.
The term xe2x80x9carylenexe2x80x9d refers to the diradical derived from aryl (including substituted aryl) as defined above and is exemplified by 1,2-phenylene, 1,3-phenylene, 1,4-phenylene, 1,2-naphthylene and the like.
The term xe2x80x9caminoxe2x80x9d refers to the group xe2x80x94NH2.
The term xe2x80x9csubstituted aminoxe2x80x9d refers to the group xe2x80x94NRR where each R is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, cycloalkenyl, substituted cycloalkenyl, alkynyl, substituted alkynyl, aryl, heteroaryl and heterocyclic provided that both R""s are not hydrogen.
xe2x80x9cAmino acidxe2x80x9d refers to any of the naturally occurring amino acids (e.g. Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Hyl, Hyp, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, and Val) in D, L, or DL form. The side chains of naturally occurring amino acids are well known in the art and include, for example, hydrogen (e.g., as in glycine), alkyl (e.g., as in alanine, valine, leucine, isoleucine, proline), substituted alkyl (e.g., as in threonine, serine, methionine, cysteine, aspartic acid, asparagine, glutamic acid, glutamine, arginine, and lysine), alkaryl (e.g., as in phenylalanine and tryptophan), substituted arylalkyl (e.g., as in tyrosine), and heteroarylalkyl (e.g., as in histidine).
The term xe2x80x9ccarboxyxe2x80x9d refers to xe2x80x94COOH.
The term xe2x80x9cC-terminusxe2x80x9d as it relates to a glycopeptide is well understood in the art. For example, for a glycopeptide of formula I, the C-terminus is the position substituted by the group R3.
The term xe2x80x9cdicarboxy-substituted alkylxe2x80x9d refers to an alkyl group substituted with two carboxy groups. This term includes, by way of example, xe2x80x94CH2(COOH)CH2COOH and xe2x80x94CH2(COOH)CH2CH2COOH.
The term xe2x80x9ccarboxyalkylxe2x80x9d or xe2x80x9calkoxycarbonylxe2x80x9d refers to the groups xe2x80x9cxe2x80x94C(O)O-alkylxe2x80x9d, xe2x80x9cxe2x80x94C(O)O-substituted alkylxe2x80x9d, xe2x80x9cxe2x80x94C(O)O-cycloalkylxe2x80x9d, xe2x80x9cxe2x80x94C(O)O-substituted cycloalkylxe2x80x9d, xe2x80x9cxe2x80x94C(O)O-alkenylxe2x80x9d, xe2x80x9cxe2x80x94C(O)O-substituted alkenylxe2x80x9d, xe2x80x9cxe2x80x94C(O)O-alkynylxe2x80x9d and xe2x80x9cxe2x80x94C(O)O-substituted alkynylxe2x80x9d where alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl and substituted alkynyl alkynyl are as defined herein.
The term xe2x80x9ccycloalkylxe2x80x9d refers to cyclic alkyl groups of from 3 to 20 carbon atoms having a single cyclic ring or multiple condensed rings. Such cycloalkyl groups include, by way of example, single ring structures such as cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl, and the like, or multiple ring structures such as adamantanyl, and the like.
The term xe2x80x9csubstituted cycloalkylxe2x80x9d refers to cycloalkyl groups having from 1 to 5 substituents, and preferably 1 to 3 substituents, selected from the group consisting of alkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl, keto, thioketo, carboxy, carboxyalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclic, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, xe2x80x94SO-alkyl, xe2x80x94SO-substituted alkyl, xe2x80x94SO-aryl, xe2x80x94SO-heteroaryl, xe2x80x94SO2-alkyl, xe2x80x94SO2-substituted alkyl, xe2x80x94SO2-aryl and xe2x80x94SO2-heteroaryl.
The term xe2x80x9ccycloalkenylxe2x80x9d refers to cyclic alkenyl groups of from 4 to 20 carbon atoms having a single cyclic ring and at least one point of internal unsaturation. Examples of suitable cycloalkenyl groups include, for instance, cyclobut-2-enyl, cyclopent-3-enyl, cyclooct-3-enyl and the like.
The term xe2x80x9csubstituted cycloalkenylxe2x80x9d refers to cycloalkenyl groups having from 1 to 5 substituents, and preferably 1 to 3 substituents, selected from the group consisting of alkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl, keto, thioketo, carboxy, carboxyalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclic, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, xe2x80x94SO-alkyl, xe2x80x94SO-substituted alkyl, xe2x80x94SO-aryl, xe2x80x94SO-heteroaryl, xe2x80x94SO2-alkyl, xe2x80x94SO2-substituted alkyl, xe2x80x94SO2-aryl and xe2x80x94SO2-heteroaryl.
The term xe2x80x9chaloxe2x80x9d or xe2x80x9chalogenxe2x80x9d refers to fluoro, chloro, bromo and iodo.
xe2x80x9cHaloalkylxe2x80x9d refers to alkyl as defined herein substituted by 1-4 halo groups as defined herein, which may be the same or different. Representative haloalkyl groups include, by way of example, trifluoromethyl, 3-fluorododecyl, 12,12,12-trifluorododecyl, 2-bromooctyl, 3-bromo-6-chloroheptyl, and the like.
The term xe2x80x9cheteroarylxe2x80x9d refers to an aromatic group of from 1 to 15 carbon atoms and 1 to 4 heteroatoms selected from oxygen, nitrogen and sulfur within at least one ring (if there is more than one ring).
Unless otherwise constrained by the definition for the heteroaryl substituent, such heteroaryl groups can be optionally substituted with 1 to 5 substituents, preferably 1 to 3 substituents, selected from the group consisting of acyloxy, hydroxy, thiol, acyl, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, substituted alkyl, substituted alkoxy, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted cycloalkenyl, amino, substituted amino, aminoacyl, acylamino, alkaryl, aryl, aryloxy, azido, carboxy, carboxyalkyl, cyano, halo, nitro, heteroaryl, heteroaryloxy, heterocyclic, heterocyclooxy, aminoacyloxy, oxyacylamino, thioalkoxy, substituted thioalkoxy, thioaryloxy, thioheteroaryloxy, xe2x80x94SO-alkyl, xe2x80x94SO-substituted alkyl, xe2x80x94SO-aryl, xe2x80x94SO-heteroaryl, xe2x80x94SO2-alkyl, xe2x80x94SO2-substituted alkyl, xe2x80x94SO2-aryl, xe2x80x94SO2-heteroaryl and trihalomethyl. Preferred aryl substituents include alkyl, alkoxy, halo, cyano, nitro, trihalomethyl, and thioalkoxy. Such heteroaryl groups can have a single ring (e.g., pyridyl or furyl) or multiple condensed rings (e.g., indolizinyl or benzothienyl). Preferred heteroaryls include pyridyl, pyrrolyl and furyl.
xe2x80x9cHeteroarylalkylxe2x80x9d refers to (heteroaryl)alkyl- where heteroaryl and alkyl are as defined herein. Representative examples include 2-pyridylmethyl and the like.
The term xe2x80x9cheteroaryloxyxe2x80x9d refers to the group heteroaryl-Oxe2x80x94.
The term xe2x80x9cheteroarylenexe2x80x9d refers to the diradical group derived from heteroaryl (including substituted heteroaryl), as defined above, and is exemplified by the groups 2,6-pyridylene, 2,4-pyridiylene, 1,2-quinolinylene, 1,8-quinolinylene, 1,4-benzofuranylene, 2,5-pyridnylene, 2,5-indolenyl and the like.
The term xe2x80x9cheterocyclexe2x80x9d or xe2x80x9cheterocyclicxe2x80x9d refers to a monoradical saturated or unsaturated group having a single ring or multiple condensed rings, from 1 to 40 carbon atoms and from 1 to 10 hetero atoms, preferably 1 to 4 heteroatoms, selected from nitrogen, sulfur, phosphorus, and/or oxygen within the ring.
Unless otherwise constrained by the definition for the heterocyclic substituent, such heterocyclic groups can be optionally substituted with 1 to 5, and preferably 1 to 3 substituents, selected from the group consisting of alkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl, keto, thioketo, carboxy, carboxyalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclic, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, xe2x80x94SO-alkyl, xe2x80x94SO-substituted alkyl, xe2x80x94SO-aryl, xe2x80x94SO-heteroaryl, xe2x80x94SO2-alkyl, xe2x80x94SO2-substituted alkyl, xe2x80x94SO2-aryl, oxo (xe2x95x90O), and xe2x80x94SO2-heteroaryl. Such heterocyclic groups can have a single ring or multiple condensed rings. Preferred heterocyclics include morpholino, piperidinyl, and the like.
Examples of nitrogen heterocycles and heteroaryls include, but are not limited to, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthylpyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, phenanthroline, isothiazole, phenazine, isoxazole, phenoxazine, phenothiazine, imidazolidine, imidazoline, piperidine, piperazine, indoline, morpholino, piperidinyl, tetrahydrofuranyl, and the like as well as N-alkoxy-nitrogen containing heterocycles.
Another class of heterocyclics is known as xe2x80x9ccrown compoundsxe2x80x9d which refers to a specific class of heterocyclic compounds having one or more repeating units of the formula [xe2x80x94(CH2xe2x80x94)aAxe2x80x94] where a is equal to or greater than 2, and A at each separate occurrence can be O, N, S or P. Examples of crown compounds include, by way of example only, [xe2x80x94(CH2)3xe2x80x94NHxe2x80x94]3, [xe2x80x94((CH2)2xe2x80x94O)4xe2x80x94((CH2)2xe2x80x94NH)2] and the like. Typically such crown compounds can have from 4 to 10 heteroatoms and 8 to 40 carbon atoms.
The term xe2x80x9cheterocyclooxyxe2x80x9d refers to the group heterocyclic-Oxe2x80x94.
The term xe2x80x9cthioheterocyclooxyxe2x80x9d refers to the group heterocyclic-Sxe2x80x94.
The term xe2x80x9cN-terminusxe2x80x9d as it relates to a glycopeptide is well understood in the art. For example, for a glycopeptide of formula II, the N-terminus is the position substituted by the group R19 and R20.
The term xe2x80x9coxyacylaminoxe2x80x9d or xe2x80x9caminocarbonyloxyxe2x80x9d refers to the group xe2x80x94OC(O)NRR where each R is independently hydrogen, alkyl, substituted alkyl, aryl, heteroaryl, or heterocyclic wherein alkyl, substituted alkyl, aryl, heteroaryl and heterocyclic are as defined herein.
The term xe2x80x9cphosphonoxe2x80x9d refers to xe2x80x94PO3H2.
The term xe2x80x9cphosphonomethylaminoxe2x80x9d refers to xe2x80x94NHxe2x80x94CH2xe2x80x94P(O)(OH)2.
The term xe2x80x9cphosphonomethylaminomethylxe2x80x9d refers to xe2x80x94CH2xe2x80x94NHxe2x80x94CH2xe2x80x94P(O)(OH)2.
The term xe2x80x9cprodrugxe2x80x9d is well understood in the art and includes compounds that are converted to pharmaceutically active compounds of the invention in a mammalian system. For example, see Remington""s Pharmaceutical Sciences, 1980, vol. 16, Mack Publishing Company, Easton, Pa., 61 and 424.
The term xe2x80x9cR-terminusxe2x80x9d as it relates to a glycopeptide is well understood in the art. For example, for a glycopeptide of formula I, the R-terminus is the position substituted by the group R5.
The term xe2x80x9csaccharide groupxe2x80x9d refers to an oxidized, reduced or substituted saccharide monoradical covalently attached to the glycopeptide or other compound via any atom of the saccharide moiety, preferably via the aglycone carbon atom. The term includes amino-containing saccharide groups. Representative saccharide include, by way of illustration, hexoses such as D-glucose, D-mannose, D-xylose, D-galactose, vancosamine, 3-desmethyl-vancosamine, 3-epi-vancosamine, 4-epi-vancosamine, acosamine, actinosamine, daunosamine, 3-epi-daunosamine, ristosamine, D-glucamine, N-methyl-D-glucamine, D-glucuronic acid, N-acetyl-D-glucosamine, N-acetyl-D-galactosamine, sialyic acid, iduronic acid, L-fucose, and the like; pentoses such as D-ribose or D-arabinose; ketoses such as D-ribulose or D-fructose; disaccharides such as 2-O-(xcex1-L-vancosaminyl)-xcex2-D-glucopyranose, 2-O-(3-desmethyl-xcex1-L-vancosaminyl)-xcex2-D-glucopyranose, sucrose, lactose, or maltose; derivatives such as acetals, amines, acylated, sulfated and phosphorylated sugars; oligosaccharides having from 2 to 10 saccharide units. For the purposes of this definition, these saccharide are referenced using conventional three letter nomenclature and the saccharide can be either in their open or preferably in their pyranose form.
The term xe2x80x9camino-containing saccharide groupxe2x80x9d refers to a saccharide group having an amino substituent. Representative amino-containing saccharide include L-vancosamine, 3-desmethyl-vancosamine, 3-epi-vancosamine, 4-epi-vancosamine, acosamine, actinosamine, daunosamine, 3-epi-daunosamine, ristosamine, N-methyl-D-glucamine and the like.
The term xe2x80x9cspiro-attached cycloalkyl groupxe2x80x9d refers to a cycloalkyl group attached to another ring via one carbon atom common to both rings.
The term xe2x80x9cstereoisomerxe2x80x9d as it relates to a given compound is well understood in the art, and refers another compound having the same molecular formula, wherein the atoms making up the other compound differ in the way they are oriented in space, but wherein the atoms in the other compound are like the atoms in the given compound with respect to which atoms are joined to which other atoms (e.g. an enantiomer, a diastereomer, or a geometric isomer). See for example, Morrison and Boyde Organic Chemistry, 1983, 4th ed., Allyn and Bacon, Inc., Boston, Mass., page 123
The term xe2x80x9csulfonamidexe2x80x9d refers to a group of the formula xe2x80x94SO2NRR, where each R is independently hydrogen, alkyl, substituted alkyl, aryl, heteroaryl, or heterocyclic wherein alkyl, substituted alkyl, aryl, heteroaryl and heterocyclic are as defined herein.
The term xe2x80x9cthiolxe2x80x9d refers to the group xe2x80x94SH.
The term xe2x80x9cthioalkoxyxe2x80x9d refers to the group xe2x80x94S-alkyl.
The term xe2x80x9csubstituted thioalkoxyxe2x80x9d refers to the group xe2x80x94S-substituted alkyl.
The term xe2x80x9cthioaryloxyxe2x80x9d refers to the group aryl-Sxe2x80x94 wherein the aryl group is as defined above including optionally substituted aryl groups also defined above.
The term xe2x80x9cthioheteroaryloxyxe2x80x9d refers to the group heteroaryl-Sxe2x80x94 wherein the heteroaryl group is as defined above including optionally substituted aryl groups as also defined above.
The term xe2x80x9cthioether derivativesxe2x80x9d when used to refer to the glycopeptide compounds of this invention includes thioethers (xe2x80x94Sxe2x80x94), sulfoxides (xe2x80x94SOxe2x80x94) and sulfones (xe2x80x94SO2xe2x80x94).
As to any of the above groups which contain one or more substituents, it is understood, of course, that such groups do not contain any substitution or substitution patterns which are sterically impractical and/or synthetically non-feasible. In addition, the compounds of this invention include all stereochemical isomers arising from the substitution of these compounds.
xe2x80x9cCyclodextrinxe2x80x9d includes cyclic molecules containing six or more xcex1-D-glucopyranose units linked at the 1,4 positions by a linkages as in amylose. xcex2-Cyclodextrin or cycloheptaamylose contains seven xcex1-D-glucopyranose units. As used herein, the term xe2x80x9ccyclodextrinxe2x80x9d also includes cyclodextrin derivatives such as hydroxypropyl and sulfobutyl ether cyclodextrins. Such derivatives are described for example, in U.S. Pat. Nos. 4,727,064 and 5,376,645. One preferred cyclodextrin is hydroxypropyl xcex2-cyclodextrin having a degree of substitution of from about 4.1-5.1 as measured by FTIR. Such a cyclodextrin is available from Cerestar (Hammond, Ind., USA) under the name Cavitron(trademark) 82003.
xe2x80x9cGlycopeptidexe2x80x9d refers to oligopeptide (e.g. heptapeptide) antibiotics (dalbaheptides), characterized by a multi-ring peptide core optionally substituted with saccharide groups, such as vancomycin. Examples of glycopeptides included in this definition may be found in xe2x80x9cGlycopeptides Classification, Occurrence, and Discoveryxe2x80x9d, by Raymond C. Rao and Louise W. Crandall, (xe2x80x9cDrugs and the Pharmaceutical Sciencesxe2x80x9d Volume 63, edited by Ramakrishnan Nagarajan, published by Marcal Dekker, Inc.). Additional examples of glycopeptodes are disclosed in U.S. Pat. Nos. 4,639,433; 4,643,987; 4,497,802; 4,698,327; 5,591,714; 5,840,684; and 5,843,889; in EP 0 802 199; EP 0 801 075; EP 0 667 353; WO 97/28812; WO 97/38702; WO 98/52589; WO 98/52592; and in J. Amer. Chem. Soc., 1996,118, 13107-13108; J. Amer. Chem. Soc., 1997, 119, 12041-12047; and J. Amer. Chem. Soc., 1994, 116, 4573-4590. Representative glycopeptides include those identified as A477, A35512, A40926, A41030, A42867, A47934, A80407, A82846, A83850 ,A84575, AB-65, Actaplanin, Actinoidin, Ardacin, Avoparcin, Azureomycin, Balhimycin, Chloroorientiein, Chloropolysporin, Decaplanin, N-demethylvancomycin, Eremomycin, Galacardin, Helvecardin, Izupeptin, Kibdelin, LL-AM374, Mannopeptin, MM45289, MM47756, MM47761, MM49721, MM47766, MM55260, MM55266, MM55270, MM56597, MM56598, OA-7653, Orenticin, Parvodicin, Ristocetin, Ristomycin, Synmonicin, Teicoplanin, UK-68597, UK-69542, UK-72051, Vancomycin, and the like. The term xe2x80x9cglycopeptidexe2x80x9d as used herein is also intended to include the general class of peptides disclosed above on which the sugar moiety is absent, i.e. the aglycone series of glycopeptides. For example, removal of the disaccharide moiety appended to the phenol on vancomycin by mild hydrolysis gives vancomycin aglycone. Also within the scope of the invention are glycopeptides that have been further appended with additional saccharide residues, especially aminoglycosides, in a manner similar to vancosamine.
xe2x80x9cOptionalxe2x80x9d or xe2x80x9coptionallyxe2x80x9d means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. For example, xe2x80x9coptionally substitutedxe2x80x9d means that a group may or may not be substituted with the described substitutent.
As used herein, the terms xe2x80x9cinert organic solventxe2x80x9d or xe2x80x9cinert solventxe2x80x9d or xe2x80x9cinert diluentxe2x80x9d mean a solvent or diluent which is essentially inert under the conditions of the reaction in which it is employed as a solvent or diluent. Representative examples of materials which may be used as inert solvents or diluents include, by way of illustration, benzene, toluene, acetonitrile, tetrahydrofuran (xe2x80x9cTHFxe2x80x9d), dimethylformamide (xe2x80x9cDMFxe2x80x9d), chloroform (xe2x80x9cCHCl3xe2x80x9d), methylene chloride (or dichloromethane or xe2x80x9cCH2Cl2), diethyl ether, ethyl acetate, acetone, methylethyl ketone, methanol, ethanol, propanol, isopropanol, tert-butanol, dioxane, pyridine, and the like. Unless specified to the contrary, the solvents used in the reactions of the present invention are inert solvents.
The term xe2x80x9cnitrogen-linkedxe2x80x9d or xe2x80x9cN-linkedxe2x80x9d means a group or substituent is attached to the remainder of a compound (e.g. a compound of formula I) through a bond to a nitrogen of the group or substituent. The term xe2x80x9coxygen-linkedxe2x80x9d means a group or substituent is attached to the remainder of a compound (e.g. a compound of formula I) through a bond to an oxygen of the group or substituent. The term xe2x80x9csulfur-linkedxe2x80x9d means a group or substituent is attached to the remainder of a compound (e.g. a compound of formula I) through a bond to a sulfur of the group or substituent.
xe2x80x9cPharmaceutically acceptable saltxe2x80x9d means those salts which retain the biological effectiveness and properties of the parent compounds and which are not biologically or otherwise harmful as the dosage administered. The compounds of this invention are capable of forming both acid and base salts by virtue of the presence of amino and carboxy groups respectively.
Pharmaceutically acceptable base addition salts may be prepared from inorganic and organic bases. Salts derived from inorganic bases include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines, substituted amines including naturally-occurring substituted amines, and cyclic amines, including isopropylamine, trimethyl amine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, tromethamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, N-alkylglucamines, theobromine, purines, piperazine, piperidine, and N-ethylpiperidine. It should also be understood that other carboxylic acid derivatives would be useful in the practice of this invention, for example carboxylic acid amides, including carboxamides, lower alkyl carboxamides, di(lower alkyl) carboxamides, and the like.
Pharmaceutically acceptable acid addition salts may be prepared from inorganic and organic acids. Salts derived from inorganic acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like. Salts derived from organic acids include acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.
The compounds of this invention typically contain one or more chiral centers. Accordingly, this invention is intended to include racemic mixtures, diasteromers, enantiomers and mixture enriched in one or more steroisomer. The scope of the invention as described and claimed encompasses the racemic forms of the compounds as well as the individual enantiomers and non-racemic mixtures thereof.
The term xe2x80x9ctreatmentxe2x80x9d as used herein includes any treatment of a condition or disease in an animal, particularly a mammal, more particularly a human, and includes:
(i) preventing the disease or condition from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it;
(ii) inhibiting the disease or condition, i.e. arresting its development; relieving the disease or condition, i.e. causing regression of the condition; or. relieving the conditions caused by the disease, i.e. symptoms of the disease.
The term xe2x80x9cdisease state which is alleviated by treatment with a broad spectrum antibacterialxe2x80x9d or xe2x80x9cbacterial diseasexe2x80x9d as used herein is intended to cover all disease states which are generally acknowledged in the art to be usefully treated with a broad spectrum antibacterial in general, and those disease states which have been found to be usefully treated by the specific antibacterials of this invention. Such disease states include, but are not limited to, treatment of a mammal afflicted with pathogenic bacteria, in particular staphylococci (methicillin sensitive and resistant), streptococci (penicillin sensitive and resistant), enterococci (vancomycin sensitive and resistant), and Clostridium difficile.
The term xe2x80x9ctherapeutically effective amountxe2x80x9d refers to that amount which is sufficient to effect treatment, as defined herein, when administered to a mammal in need of such treatment. The therapeutically effective amount will vary depending on the subject and disease state being treated, the severity of the affliction and the manner of administration, and may be determined routinely by one of ordinary skill in the art.
The term xe2x80x9cprotecting groupxe2x80x9d or xe2x80x9cblocking groupxe2x80x9d refers to any group which, when bound to one or more hydroxyl, thiol, amino, carboxy or other groups of the compounds, prevents undesired reactions from occurring at these groups and which protecting group can be removed by conventional chemical or enzymatic steps to reestablish the hydroxyl, thio, amino, carboxy or other group. The particular removable blocking group employed is not critical and preferred removable hydroxyl blocking groups include conventional substituents such as allyl, benzyl, acetyl, chloroacetyl, thiobenzyl, benzylidine, phenacyl, t-butyl-diphenylsilyl and any other group that can be introduced chemically onto a hydroxyl functionality and later selectively removed either by chemical or enzymatic methods in mild conditions compatible with the nature of the product. Protecting groups are disclosed in more detail in T. W. Greene and P. G. M. Wuts, xe2x80x9cProtective Groups in Organic Synthesisxe2x80x9d 3rd Ed., 1999, John Wiley and Sons, N.Y.
Preferred removable amino blocking groups include conventional substituents such as t-butyoxycarbonyl (t-BOC), benzyloxycarbonyl (CBZ), fluorenylmethoxycarbonyl (FMOC), allyloxycarbonyl (ALOC) and the like, which can be removed by conventional conditions compatible with the nature of the product.
Preferred carboxy protecting groups include esters such as methyl, ethyl, propyl, t-butyl etc. which can be removed by mild conditions compatible with the nature of the product.
xe2x80x9cVancomycinxe2x80x9d refers to a glycopeptide antibiotic having the formula: 
When describing vancomycin derivatives, the term xe2x80x9cNvan-xe2x80x9d indicates that a substituent is covalently attached to the amino group of the vacosamine moiety of vacomycin. Similarly, the term xe2x80x9cNleu-xe2x80x9d indicates that a substituent is covalently attached to the amino group of the leucine moiety of vancomycin.
The glycopeptide compounds of this invention can be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures.
Additionally, as will be apparent to those skilled in the art, conventional protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions. The choice of a suitable protecting group for a particular functional group as well as suitable conditions for protection and deprotection are well known in the art. For example, numerous protecting groups, and their introduction and removal, are described in T. W. Greene and G. M. Wuts, Protecting Groups in Organic Synthesis, Third Edition, Wiley, New York, 1999, and references cited therein.
In the following reaction schemes, the glycopeptide compounds are depicted in a simplified form as a box xe2x80x9cGxe2x80x9d that shows the carboxy terminus labeled [C], the vancosamine amino terminus labeled [V], the xe2x80x9cnon-saccharidexe2x80x9d amino terminus (leucine amine moiety) labeled [N], and optionally, the resorcinol moiety labeled [R] as follows: 
A glycopeptide compound of the present invention, which is substituted at the C-terminus with a substituent that comprises one or more (e.g. 1, 2, 3, 4, or 5) phosphono (xe2x80x94PO3H2) groups, can be prepared by coupling a corresponding glycopeptide compound wherein the C-terminus is a carboxy group with a suitable phosphono containing compound. For example, a glycopeptide compound wherein the C-terminus is a carboxy group can be coupled with a phosphono containing amine, alcohol, or thiol compound to form an amide, an ester, or a thioester, respectively. For example a glycopeptide compound of formula I wherein R3 is a nitrogen linked moiety comprising one or more phosphono groups can be prepared by coupling a corresponding glycopeptide compound of formula I wherein R3 is hydroxy with the requisite phosphono-containing amine to form the formula I wherein R3 is a nitrogen linked moiety comprising one or more phosphono groups.
A glycopeptide compound of the present invention, which is substituted at the C-terminus with a substituent that comprises one or more (e.g. 1, 2, 3, 4, or 5) phosphono (xe2x80x94PO3H2) groups, and wherein the vancosamine amino terminus (V) is substituted, can be prepared by first reductively alkylating the corresponding glycopeptide compound wherein the vancosamine amino terminus (V) is the free amine (NH2) and then coupling the corresponding glycopeptide compound with the requisite phosphono containing compound (e.g. phosphono containing amine, alcohol, or thiol).
By way of illustration, a glycopeptide compound, such as vancomycin, can first be reductive alkylated as shown in the following reaction: 
where A represents Ra minus one carbon atom and Ra, Rb, Y, Z and x are as defined herein. This reaction is typically conducted by first contacting one equivalent of the glycopeptide, i.e., vancomycin, with an excess, preferably from 1.1 to 1.3 equivalents, of the desired aldehyde in the presence of an excess, preferably about 2.0 equivalents, of a tertiary amine, such as diisopropylethylamine (DIPEA) and the like. This reaction is typically conducted in an inert diluent, such as DMF or acetonitrile/water, at ambient temperature for about 0.25 to 2 hours until formation of the corresponding imine and/or hemiaminal is substantially complete. The resulting imine and/or hemiaminal is typically not isolated, but is reacted in situ with a reducing agent, such as sodium cyanoborohydride, pyridine borane, or the like, to afford the corresponding amine. This reaction is preferably conducted by contacting the imine and/or hemiaminal with an excess, preferably about 3 equivalents, of trifluoroacetic acid, followed by about 1 to 1.2 equivalents of the reducing agent at ambient temperature in methanol or acetonitrile/water. The resulting alkylated product is readily purified by conventional procedures, such as precipitation and/or reverse-phase HPLC. Surprisingly, by forming the imine and/or hemiaminal in the presence of a trialkyl amine, and then acidifying with trifluoroacetic acid before contact with the reducing agent, the selectivity for the reductive alkylating reaction is greatly improved, i.e., reductive alkylating at the amino group of the saccharide (e.g., vancosamine) is favored over reductive alkylating at the N-terminus (e.g., the leucinyl group) by at least 10:1, more preferably 20:1.
The above process is a significantly improvement over previous methods for selectively alkylating an amino saccharide group of a glycopeptide antibiotic. Thus, the present invention also provides a method for alkylating a glycopeptide that comprises a saccharide-amine comprising:
combining an aldehyde or ketone, a suitable base, and the glycopeptide, to provide a reaction mixture;
acidifying the reaction mixture; and
combining the reaction mixture with a suitable reducing agent, to provide a glycopeptide that is alkylated at the saccharide-amine. Preferably, the glycopeptide comprises at least one amino group other than the saccharide-amine.
Preferably, the reductive alkylating at the saccharide-amine is favored over reductive alkylating at another amino group of the glycopeptide by at least about 10:1; and more preferably, by at least about 15:1 or about 20:1.
The reductive alkylating process of the invention is typically carried out in the presence of a suitable solvent or combination of solvents, such as, for example, a halogenated hydrocarbon (e.g. methylene chloride), a linear or branched ether (e.g. diethyl ether, tetrahydrofuran), an aromatic hydrocarbon (e.g. benzene or toluene), an alcohol (methanol, ethanol, or isopropanol), dimethylsulfoxide (DMSO), N,N-dimethylformamide, acetonitrile, water, 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidone, tetramethyl urea, N,N-dimethylacetamide, diethylformamide (DMF), 1-methyl-2-pyrrolidinone, tetramethylenesulfoxide, glycerol, ethyl acetate, isopropyl acetate, N,N-dimethylpropylene urea (DMPU) or dioxane. Preferably the alkylating is carried out in acetonitrile/water, or DMF/methanol.
Preferably the reduction (i.e. treatment with the reducing agent) is carried out in the presence of a protic solvent, such as, for example, an alcohol (e.g. methanol, ethanol, propanol, isopropanol, or butanol), water, or the like.
The reductive alkylating process of the invention can be carried out at any suitable temperature from the freezing point to the reflux temperature of the reaction mixture. Preferably the reaction is carried out at a temperature in the range of about 0xc2x0 C. to about 100xc2x0 C. More preferably at a temperature in a range of about 0xc2x0 C. to about 50xc2x0 C., or in a range of about 20xc2x0 C. to about 30xc2x0 C.
Any suitable base can be employed in the reductive alkylating process of the invention. Suitable bases include tertiary amines (e.g. diisopropylethylamine, N-methylmorpholine or triethylamine) and the like.
Any suitable acid can be used to acidify the reaction mixture. Suitable acids include carboxylic acids (e.g. acetic acid, trichloroacetic acid, citric acid, formic acid, or trifluoroacetic acid), mineral acids (e.g. hydrochloric acid, sulfuric acid, or phosphoric acid), and the like. A preferred acid is trifluoroacetic acid.
Suitable reducing agents for carrying out reductive alkylating process of the invention are known in the art. Any suitable reducing agent can be employed in the methods of the invention, provided it is compatible with the functionality present in the glycopeptide. For example, suitable reducing agents include sodium cyanoborohydride, sodium triacetoxyborohydride, pyridine/borane, sodium borohydride, and zinc borohydride. The reduction can also be carried out in the presence of a transition metal catalyst (e.g. palladium or platinum) in the presence of a hydrogen source (e.g. hydrogen gas or cyclohexadiene). See for example, Advanced Organic Chemistry, Fourth Edition, John Wiley and Sons, New York (1992), 899-900.
The glycopeptide derivative resulting from the reductive alkylating is then coupled with a phosphono containing amine (R3xe2x80x94H) to form an amide bond. This reaction is illustrated by the following reaction: 
where R3 is a nitrogen-linked group that comprises one or more phosphono groups. In this reaction, the glycopeptide derivative is typically contacted with the amine in the presence of a peptide coupling reagent, such as PyBOP and HOBT, to provide the amide. This reaction is typically conducted in an inert diluent, such as DMF, at a temperature ranging from about 0xc2x0 C. to about 60xc2x0 C. for about 1 to 24 hours or until the coupling reaction is substantially complete. Subsequent deprotection using conventional procedures and reagents affords the compound of this invention.
If desired, the amine coupling step described above can be conducted first to provide an amide, followed by reductive alkylating and deprotection to afford the compound of the invention.
If desired, the glycopeptide compounds of this invention can also be prepared in a step-wise manner in which a precursor to the xe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x, group is first attached the glycopeptide by reductive alkylating, followed by subsequent elaboration of the attached precursor using conventional reagent and procedures to form the xe2x80x94Raxe2x80x94Yxe2x80x94Rbxe2x80x94(Z)x, group. Additionally, ketones may also be employed in the above-described reductive alkylating reactions to afford a-substituted amines.
Any glycopeptide having an amino group may be employed in these reductive alkylating reactions. Such glycopeptides are well-known in the art and are either commercially available or may be isolated using conventional procedures. Suitable glycopeptides are disclosed, by way of example, in U.S. Pat. Nos. 3,067,099; 3,338,786; 3,803,306; 3,928,571; 3,952,095; 4,029,769; 4,051,237; 4,064,233; 4,122,168; 4,239,751; 4,303,646; 4,322,343; 4,378,348; 4,497,802; 4,504,467; 4,542,018; 4,547,488; 4,548,925; 4,548,974; 4,552,701; 4,558,008; 4,639,433; 4,643,987; 4,661,470; 4,694,069; 4,698,327; 4,782,042; 4,914,187; 4,935,238; 4,946,941; 4,994,555; 4,996,148; 5,187,082; 5,192,742; 5,312,738; 5,451,570; 5,591,714; 5,721,208; 5,750,509; 5,840,684; and 5,843,889. Preferably, the glycopeptide employed in the above reaction is vancomycin.
As illustrated in the following scheme, a phosphono containing aminoalkyl sidechain at the resorcinol moiety of a glycopeptide, such as vancomycin, can be introduced via a Mannich reaction (in this scheme, the resorcinol moiety of the glycopeptide is illustrated for clarity). In this reaction, an amine of formula NHRRxe2x80x2 (wherein one or both of R and Rxe2x80x2 is a group that comprises one or more phosphono groups), and an aldehyde (e.g. CH2O), such as formalin (a source of formaldehyde), are reacted with the glycopeptide under basic conditions to give the glycopeptide derivative. 
Compounds of the invention comprising a sulfoxide or sulfone can be prepared from the corresponding thio compounds using conventional reagents and procedures. Suitable reagents for oxidizing a thio compound to a sulfoxide include, by way of example, hydrogen peroxide, peracides such as 3-chloroperoxybenzoic acid (MCPBA), sodium periodate, sodium chlorite, sodium hypochlorite, calcium hypochlorite, tert-butyl hypochlorite and the like. Chiral oxidizing reagents, (optically active reagents) may also be employed to provide chiral sulfoxides. Such optically active reagents are well-known in the art and include, for example, the reagents described in Kagen et al., Synlett., 1990, 643-650.
The aldehydes and ketones employed in the above reactive alkylating reactions are also well-known in the art and are either commercially available or can be prepared by conventional procedures using commercially available starting materials and conventional reagents (for example see March, Advanced Organic Chemistry, Fourth Edition, John Wiley and Sons, New York (1992), and references cited therein).
The phosphono substituted compounds (e.g. the phosphono substituted amines, alcohols, or thiols) are either commercially available or can be prepared by conventional procedures using commercially available starting materials and reagents. See for example, Advanced Organic Chemistry, Jerry March, 4th ed., 1992, John Wiley and Sons, New York, page 959; and Frank R. Hartley (ed.) The Chemistry of Organophosphorous Compounds, vol. 1-4, John Wiley and Sons, New York (1996). Aminomethylphosphonic acid is commercially available from Aldrich Chemical Company, Milwaukee, Wis.
Additional details and other methods for preparing the compounds of this invention are described in the Examples below.
This invention also includes pharmaceutical composition containing the novel glycopeptide compounds of this invention. Accordingly, the glycopeptide compound, preferably in the form of a pharmaceutically acceptable salt, can be formulated for oral or parenteral administration for the therapeutic or prophylactic treatment of bacterial infections.
By way of illustration, the glycopeptide compound can be admixed with conventional pharmaceutical carriers and excipients and used in the form of tablets, capsules, elixirs, suspensions, syrups, wafers, and the like. Such pharmaceutical compositions will contain from about 0.1 to about 90% by weight of the active compound, and more generally from about 10 to about 30%. The pharmaceutical compositions may contain common carriers and excipients, such as corn starch or gelatin, lactose, sucrose, microcrystalline cellulose, kaolin, mannitol, dicalcium phosphate, sodium chloride, and alginic acid. Disintegrators commonly used in the formulations of this invention include croscarmellose, microcrystalline cellulose, corn starch, sodium starch glycolate and alginic acid.
A liquid composition will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carrier(s), for example ethanol, glycerine, sorbitol, non-aqueous solvent such as polyethylene glycol, oils or water, optionally with a suspending agent, a solubilizing agent (such as a cyclodextrin), preservative, surfactant, wetting agent, flavoring or coloring agent. Alternatively, a liquid formulation can be prepared from a reconstitutable powder.
For example a powder containing active compound, suspending agent, sucrose and a sweetener can be reconstituted with water to form a suspension; and a syrup can be prepared from a powder containing active ingredient, sucrose and a sweetener.
A composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid compositions. Examples of such carriers include magnesium stearate, starch, lactose, sucrose, microcrystalline cellulose and binders, for example polyvinylpyrrolidone. The tablet can also be provided with a color film coating, or color included as part of the carrier(s). In addition, active compound can be formulated in a controlled release dosage form as a tablet comprising a hydrophilic or hydrophobic matrix.
A composition in the form of a capsule can be prepared using routine encapsulation procedures, for example by incorporation of active compound and excipients into a hard gelatin capsule. Alternatively, a semi-solid matrix of active compound and high molecular weight polyethylene glycol can be prepared and filled into a hard gelatin capsule; or a solution of active compound in polyethylene glycol or a suspension in edible oil, for example liquid paraffin or fractionated coconut oil can be prepared and filled into a soft gelatin capsule.
Tablet binders that can be included are acacia, methylcellulose, sodium carboxymethylcellulose, poly-vinylpyrrolidone (Povidone), hydroxypropyl methylcellulose, sucrose, starch and ethylcellulose. Lubricants that can be used include magnesium stearate or other metallic stearates, stearic acid, silicone fluid, talc, waxes, oils and colloidal silica.
Flavoring agents such as peppermint, oil of wintergreen, cherry flavoring or the like can also be used. Additionally, it may be desirable to add a coloring agent to make the dosage form more attractive in appearance or to help identify the product.
The compounds of the invention and their pharmaceutically acceptable salts that are active when given parenterally can be formulated for intramuscular, intrathecal, or intravenous administration.
A typical composition for intra-muscular or intrathecal administration will consist of a suspension or solution of active ingredient in an oil, for example arachis oil or sesame oil. A typical composition for intravenous or intrathecal administration will consist of a sterile isotonic aqueous solution containing, for example active ingredient and dextrose or sodium chloride, or a mixture of dextrose and sodium chloride. Other examples are lactated Ringer""s injection, lactated Ringer""s plus dextrose injection, Normosol-M and dextrose, Isolyte E, acylated Ringer""s injection, and the like. Optionally, a co-solvent, for example, polyethylene glycol; a chelating agent, for example, ethylenediamine tetracetic acid; a solubilizing agent, for example, a cyclodextrin; and an anti-oxidant, for example, sodium metabisulphite, may be included in the formulation. Alternatively, the solution can be freeze dried and then reconstituted with a suitable solvent just prior to administration.
In a preferred embodiment, the glycopeptide derivatives of this invention are formulated in an aqueous solution containing a cyclodextrin. In another preferred embodiment the glycopeptide derivatives of this invention are formulated as a lyophilized powder containing a cyclodextrin or as a sterile powder containing a cyclodextrin. Preferably, the cyclodextrin is hydroxypropyl-xcex2-cyclodextrin or sulfobutyl ether xcex2-cyclodextrin; more preferably, the cyclodextrin is hydroxypropyl-xcex2-cyclodextrin. Typically, in an injectable solution, the cyclodextrin will comprise about 1 to 25 weight percent; preferably, about 2 to 10 weight percent; more preferable, about 4 to 6 weight percent, of the formulation. Additionally, the weight ratio of the cyclodextrin to the glycopeptide derivative will preferably be from about 1:1 to about 10: 1.
The compounds of the invention and their pharmaceutically acceptable salts which are active on rectal administration can be formulated as suppositories. A typical suppository formulation will generally consist of active ingredient with a binding and/or lubricating agent such as a gelatin or cocoa butter or other low melting vegetable or synthetic wax or fat.
The compounds of this invention and their pharmaceutically acceptable salts which are active on topical administration can be formulated as transdermal compositions or transdermal delivery devices (xe2x80x9cpatchesxe2x80x9d). Such compositions include, for example, a backing, active compound reservoir, a control membrane, liner and contact adhesive. Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds of the present invention in controlled amounts. The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g., U.S. Pat. No. 5,023,252, issued Jun. 11, 1991. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.
The active compound is effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. It, will be understood, however, that the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered and its relative activity, the age, weight, and response of the individual patient, the severity of the patient""s symptoms, and the like.
Suitable doses are in the general range of from 0.01-100 mg/kg/day, preferably 0.1-50 mg/kg/day. For an average 70 kg human, this would amount to 0.7 mg to 7 g per day, or preferably 7 mg to 3.5 g per day. A more preferred dose for a human is about 500 mg to about 2 g per day.
Other suitable formulations for use in the present invention can be found in Remington""s Pharmaceutical Sciences, Mace Publishing Company, Philadelphia, Pa., 17th ed. (1985).
The following illustrate representative pharmaceutical compositions of the present invention.
USPTO Backgrounds
USPTO Backgrounds